,text,crowd_label,conf0,conf1,itemID
0,levonorgestrel breast cancer estim rate endometri patholog prophylact use levonorgestrel-releas intrauterin system women breast cancer treat tamoxifen,0,1.0,0.0,990
1,vinblastin nsclc patient stage iiib iv nsclc random start treatment receiv either three six cours mitomycin num mg/m num cours num num num num vinblastin num mg/m num cisplatin num2 mg/m num mvp everi num2 day,0,1.0,0.0,1499
2,atp carcinoma hypoton challeng not camp stimul found induc releas atp measur luciferin-luciferas assay murin mammari carcinoma cell line cnum3i cnum3 cell stabli transfect cdna human cystic fibrosi transmembran conduct regul cftr protein cnum3/cftr,0,1.0,0.0,2166
3,vitamin d. colorect cancer dietari intak retinol vitamin thiamin riboflavin vitamin b6 folat vitamin bnum2 vitamin calcium iron magnesium potassium n num fatti acid n num fatti acid ratio n num n num fatti acid estim associ colorect cancer examin use condit logist regress model adjust exact age height weight energi intak alcohol intak fiber intak smoke educ social class physic activ,0,0.7939,0.20609999999999995,410
4,levothyroxin hypothyroid one pregnant patient take levothyroxin hypothyroid,0,1.0,0.0,2031
5,tetracain ear infect use extemporan compound num tetracain improv adher clotrimazol num topic solut treatment ear infect case report,0,1.0,0.0,1418
6,tamoxifen breast cancer/uterin cancer num3 women identifi histori breast cancer treat tamoxifen preced diagnosi uterin cancer,0,0.7906,0.20940000000000009,387
7,dopamin impuls control disord riski busi dopamin agonist parkinson diseas impuls control disord,0,0.804,0.19599999999999995,2606
8,aspirin embol event active-w atrial fibril clopidogrel trial irbesartan prevent vascular event studi demonstr warfarin superior platelet therapi clopidogrel plu aspirin prevent af embol event,0,1.0,0.0,2616
9,terazosin hypertens data demonstr use terazosin monotherapi add-on therapi treatment hypertens,0,1.0,0.0,872
10,naltrexon alcohol disulfiram naltrexon approv food drug administr fda treatment alcohol agent not rigor evalu dualli diagnos individu,0,1.0,0.0,640
11,vemurafenib melanoma literatur access medlin intern pharmaceut abstract num4-novemb num4 use term melanoma metastat melanoma ipilimumab vemurafenib dabrafenib trametinib,0,1.0,0.0,973
12,toremifen breast cancer forty-nin postmenopaus patient node-posit breast cancer random trial compar effect tamoxifen toremifen serum lipoprotein,0,1.0,0.0,98
13,fatti acid colorect cancer vitamin miner essenti fatti acid colorect cancer risk unit kingdom dietari cohort consortium,0,1.0,0.0,1328
14,num-hydroxydeoxyguanosin cancer determin urinari num-hydroxydeoxyguanosin autom coupled-column high perform liquid chromatographi power techniqu assay vivo oxid dna damag cancer patient,0,1.0,0.0,2402
15,procarbazin rhabdomyosarcoma tumor includ childhood high-grad glioma d-num3 mg d-num3 mg adult high-grad glioma d-num2 mg d-num3 mg medulloblastoma dnum3 med dnum3 med ependymoma dnum3 ep dnum3 ep rhabdomyosarcoma te-num3 well sublin demonstr resist busulfan d-num3 mg br cyclophosphamid te-num3 cr procarbazin d-num3 mg pr melphalan te-num3 mr grow subcutan intracrani athym nude mice,0,1.0,0.0,532
16,heparin thromboembol retrospect evalu effect heparin use thromboembol bleed complic implant heartmat ii left ventricular assist devic lvad,0,0.8156,0.1844,1402
17,mtx ra acceler nodulosi mtx ra not rare occur despit good clinic respons polyarthr,0,1.0,0.0,2699
18,retino acid retino acid/ra investig effect retino acid ra retinyl acet rac product reactiv oxygen metabolit releas lysosom enzym human polymorphonuclear leukocyt pmn,0,1.0,0.0,3011
19,formoterol fumar asthmat ten asthmat patient enrol studi effect dri powder formoterol fumar,0,1.0,0.0,1964
20,polyphenol cancer addit also propos tea polyphenol function cancer chemoprevent agent modul mitot signal transduct,0,0.8044,0.1956,1138
21,ofx/ofloxacin bacteri kerat compar vitro suscept pattern minimum inhibitori concentr mic gatifloxacin gat moxifloxacin mox fourth-gener fluoroquinolon ciprofloxacin cip ofloxacin ofx second-gener fluoroquinolon levofloxacin lev third-gener fluoroquinolon use bacteri kerat isol,0,1.0,0.0,1147
22,glucos sepsi glucos prove nitrogen spare properti postop patient critic ill patient toler glucos load poorli fat appear obligatori fuel sepsi,0,0.8263,0.17369999999999994,2208
23,tzd type furthermor incid anemia end reach num group tzd num2 group acei/arb/tzdnumcoadministr ra inhibitor ppar-e_ agonist consid differenti diagnosi hematocrit lower anemia uncompl type num diabet patient normal serum creatinin,0,1.0,0.0,2861
24,corticosteroid cognit impair although patient initi stabil therapi corticosteroid plasma exchang mitoxantron sever cognit impair persist eventu die sequela diseas,0,0.7942,0.2058,1242
25,silicon myopia investig efficaci safeti stabil correct achiev silicon posterior chamber intraocular len use correct high myopia phakic eye,0,1.0,0.0,1996
26,methamphetamin hiv-num neurodegener progress understand basal ganglia dysfunct common target methamphetamin abus hiv-num neurodegener,0,1.0,0.0,628
27,bortezomib escc thu bortezomib could sensit escc trail apoptosi multipl molecular mechan action,0,0.8213,0.17869999999999994,1325
28,donepezil ad clinic trial donepezil shown improv significantli cognit global function patient mild moder sever ad demonstr excel toler safeti profil,0,1.0,0.0,2323
29,ethyl acet glycoprotein mous lymphoma present work extract num2 select herb prepar methanol chloroform ethyl acet water effect multidrug resist mdr p-glycoprotein mous lymphoma cell transfect human mdr1 gene human lung alveolar epitheli cell line investig,0,1.0,0.0,2937
30,perindopril cardiac event european trial reduct cardiac event perindopril stabl coronari arteri diseas europa trial recent report,0,1.0,0.0,548
31,dihydropyridin hypocalcem order studi role calcium ion pathogenesi vasoconstrict lesion caus acut smoke author studi peripher vascular effect calcium-channel antagonist nifedipin dihydropyridin deriv calcitonin hypocalcem hormon possess vasoact action num2 elderli regular smoker mean age num2num year,0,1.0,0.0,452
32,mpd pd mechan mpd action patient advanc pd discuss,0,1.0,0.0,1822
33,bortezomib relaps diseas bortezomib thalidomid lenalidomid improv therapeut armentarium patient refractori relaps diseas often use combin dexamethason chemotherapeut agent,0,1.0,0.0,1794
34,aspirin bleed aspirin group complic gastrointest symptom mainli epigastr pain no frank bleed observ,0,1.0,0.0,735
35,cholesterol hypercholesterolemia recent posit effect cholesterol-low drug pravastatin lovastatin npt observ middle-ag male chronic hypercholesterolemia,0,1.0,0.0,836
36,imiquimod tumor way imiquimod may act stimul notch pathway sbcc tumor cell up-regul protein express notch ligand jagged1,0,1.0,0.0,2378
37,arsen trioxid apl salvag treatment effect num/num patient num2 relaps apl long-term survivor second line combin treatment arsen trioxid num/num patient stem cell transplant num/num patient,0,1.0,0.0,1623
38,adriamycin gastric cancer knockdown mdr1 increas sensit adriamycin drug resist gastric cancer cell,0,1.0,0.0,2118
39,paclitaxel tumor/breast cancer activ rnum5 paclitaxel alon combin studi human breast cancer cell line bt-num3 overexpress her2/neu mda-mb-num3 low her2/neu cell viabil biomark farnesyl hdj-num rho b tumor growth raf/mek/erk surviv pi3k/akt angiogenesi vegf fgf-num mmp-num mmp-num mmp-num endpoint,0,1.0,0.0,2050
40,calcium hypocalcem order studi role calcium ion pathogenesi vasoconstrict lesion caus acut smoke author studi peripher vascular effect calcium-channel antagonist nifedipin dihydropyridin deriv calcitonin hypocalcem hormon possess vasoact action num2 elderli regular smoker mean age num2num year,0,1.0,0.0,582
41,nystatin mcd howev case lipid raft inhibitor nystatin beta-mcd disrupt patch,0,1.0,0.0,2192
42,progesteron bca mono-lay cell cultur model pnum2-wild type estrogen receptor er -depend mcf-num bca cell pnum2-mut er-/progesteron receptor pr her2-regular triple-neg mda-mb-num3 bca expos pgg comprehens investig cellular consequ molecular targets/medi,0,1.0,0.0,1018
43,sulfasalazine/ssz arthriti methotrex mtx sulfasalazin ssz cyclosporin csa wide use dmard treatment psa safe effect patient activ peripher arthriti although not appear effect axial manifest,0,1.0,0.0,2865
44,atorvastatin diabet atorvastatin exert benefici vascular effect diabet underli mechan yet elucid,0,1.0,0.0,1510
45,ammonia encephalopathi efficaci variabl fast postprandi ammonia concentr number-connection-test time mental state grade portosystem encephalopathi index,0,1.0,0.0,2785
46,atropin colon motil atropin use control demonstr respons select paramet colon motil,0,1.0,0.0,378
47,leuprolid prostat hyperplasia lutein hormon releas hormon agonist leuprolid investig double-blind random placebo-control studi compris num2 evalu patient moder sever symptom result benign prostat hyperplasia,0,1.0,0.0,1811
48,oxygen diabet foot ulcer aim studi evalu effect hyperbar oxygen therapi hbot manag chronic diabet foot ulcer,0,1.0,0.0,1893
49,coumadin rheumat mitral stenosi compar studi coumadin aspirin primari cardioembol stroke thromboembol prevent chronic rheumat mitral stenosi atrial fibril,0,1.0,0.0,809
50,phosphat ckd/chronic kidney diseas lanthanum carbon sevelam carbon non-calcium-bas phosphat binder use manag hyperphosphataemia patient chronic kidney diseas ckd,0,1.0,0.0,1952
51,clopidogrel embol event active-w atrial fibril clopidogrel trial irbesartan prevent vascular event studi demonstr warfarin superior platelet therapi clopidogrel plu aspirin prevent af embol event,0,1.0,0.0,2772
52,catecholamin hyperthermia urinari catecholamin hyperthermia-rel death,0,0.6057,0.3943,2621
53,irinotecan non-hodgkin 's lymphoma camptothecin deriv irinotecan cpt-num2 shown possess antitumor activ phase ii trial patient carcinoma lung cervix ovari colon rectum patient non-hodgkin 's lymphoma,0,1.0,0.0,3025
54,sulfasalazine/ssz psa methotrex mtx sulfasalazin ssz cyclosporin csa wide use dmard treatment psa safe effect patient activ peripher arthriti although not appear effect axial manifest,0,1.0,0.0,1939
55,vitamin e. cataract prior vitamin e supplement may protect vecat particip develop least earli cortic cataract,0,1.0,0.0,1356
56,sodium bicarbon death patient random receiv sodium bicarbon vs sodium chlorid rate death dialysi myocardi infarct cerebrovascular event not differ significantli num2 day num vs num num vs num num vs num num vs num respect num2 day num month num vs num num vs num num vs num num vs num respect p .num2,0,1.0,0.0,2997
57,lovastatin hypercholesterolemia recent posit effect cholesterol-low drug pravastatin lovastatin npt observ middle-ag male chronic hypercholesterolemia,0,1.0,0.0,791
58,num-mercaptopurin inflammatori bowel diseas increas dose requir num-mercaptopurin azathioprin inflammatori bowel diseas patient six year younger,0,1.0,0.0,386
59,cortisol pain aural canal core skin surfac num2 site temperatur oxygen consumpt pain visual analogu score concentr epinephrin norepinephrin glucos cortisol lactat free fatti acid plasma measur epidur blockad num2 min epidur blockad end surgeri num h surgeri,0,1.0,0.0,69
60,methadon pain increas risk death observ patient receiv methadon retrospect cohort studi even low dose support recommend not drug first choic noncanc pain,0,0.7974,0.2026,1142
61,oestrogen menstrual bleed determin effect accept progestogen alon combin oestrogen regul irregular menstrual bleed associ oligo/anovul,0,1.0,0.0,2896
62,num-mp ibd clinic data collect retrospect ibd patient num year age younger treat num-mp/aza children 's hospit philadelphia,0,0.8059999999999999,0.19400000000000006,1647
63,eosin cancer uni- multivari variabl analys show lowest recurr rate report studi perform cancer centr studi describ use num2m tc-sulphur colloid also investig use superfici inject techniqu evalu harvest sentinel node haematoxylin-eosin immunohistochemistri stain p numnum2,0,0.7955,0.2045,760
64,aldosteron renal cardiovascular morbid combin therapi calcium channel antagonist calcium channel blocker ccb inhibitor renin-angiotensin-aldosteron system raa ration approach achiev bp goal provid protect against renal cardiovascular morbid mortal,0,1.0,0.0,2942
65,dopamin schizophren homovanil acid hva oxid metabolit dopamin shown number studi reflect sever symptom predict respons neurolept treatment schizophren patient,0,0.8017,0.1983000000000001,2347
66,aza laboratori abnorm no patient discontinu num-mp/aza laboratori abnorm improv spontan dose reduct,0,0.805,0.19499999999999995,2155
67,olopatadin at twelv patient receiv ketotifen num2 olopatadin num2 at,0,1.0,0.0,855
68,argentatin a. cancer synthesi argentatin deriv growth inhibitor human cancer cell line vitro,0,1.0,0.0,1162
69,terfenadin urticaria studi done num2 outpati physic stimulus-induc urticaria num2 patient receiv nimodipin three time day daili dose num3 mg num2 patient treat terfenadin dose num3 mg,0,0.8075,0.1925,2338
70,paroxetin pruritu therefor identifi underli caus pruritu prime import order develop tailor treatment plan even palli care treatment focus toward symptom not necessarili underli disease.result show palli care patient pruritu differ natur treatment drug paroxetin select serotonin reuptak inhibitor may benefici,0,1.0,0.0,510
71,platinum bladder cancer phase ii studi vinflunin bladder cancer patient progress first-lin platinum-contain regimen,0,1.0,0.0,2816
72,lidocain heat stress progress passiv heat stress particip receiv intranas cocain num mg/kg bodi weight placebo lidocain num mg/kg,0,0.8068,0.19320000000000004,1012
73,calcium pancreat cancer no associ found pancreat cancer risk intak total fat satur fat cholesterol omega-num fatti acid vitamin c. unexpect invers associ calcium intak pancreat cancer risk data,0,0.8119,0.18810000000000004,435
74,apigenin prostat carcinoma molecular mechan apigenin-induc cell-cycl arrest apoptosi hormon refractori human prostat carcinoma dunum3 cell,0,1.0,0.0,2112
75,alcohol hepat b. conduct prospect cohort studi liver cancer korea assess independ effect interact smoke alcohol consumpt hepat b risk mortal hepatocellular carcinoma,0,1.0,0.0,917
76,creatinin atrial fibril use heparin-co circuit reduc mean length stay hospit num +/- num num +/- num day p numnum3 postop ventil time num +/- num num +/- num h p numnum3 blood loss num h post surgeri num3 +/- num3 num3 +/- num3 ml p numnum3 individu periop chang haemoglobin loss p numnum3 leukocyt count p numnum3 creatinin elev p numnum3 proport patient expos allogen blood transfus num2num vs num2num p numnum3 postop coagul disturb num vs num p numnum3 postop deviat normal postop cours num2num vs num2num p numnum3 neurolog deviat num vs num p numnum3 atrial fibril num2num vs num2num p numnum3,0,1.0,0.0,2218
77,prostaglandin e num breast cancer apoptosi induc num-hpr cox-num inhibitor combin although unaffect anti-her2/neu antibodi revers cox-num product prostaglandin e num indic cox-num major mechan her2/neu suppress num-hpr apoptosi breast cancer cell,0,1.0,0.0,2077
78,sirolimu hcv review num4 liver recipi num4 num4 identifi cohort hcv recipi expos sirolimu primari immunosuppress srl cohort hcv control group recipi never receiv sirolimu,0,1.0,0.0,1875
79,eicosanoid inflamm aim studi determin quantiti produc mediat inflamm cytokin eicosanoid carotid endarterectomi cea factor ischem damag brain,0,0.6004,0.3996,1457
80,cephalosporin tubular marker protein order assess nephrotox potenti antibiot variou aminoglycosid cephalosporin test potenc alter excret tubular marker protein brush border antigen chang normal pattern serumproteinuria analyz sd polyacrylamidgel gradient electrophoresi,0,0.7959,0.20409999999999995,1853
81,cisplatin tumour cisplatin remain princip chemotherapi agent treatment mani solid tumour,0,1.0,0.0,146
82,methotrexate/mtx acut lymphoblast leukemia/al methotrex mtx import compon therapi pediatr acut lymphoblast leukemia,0,1.0,0.0,800
83,rifampicin tuberculosi rifampicin resist risk factor poor outcom tuberculosi,0,0.8181,0.18189999999999995,963
84,num-deoxyglucos stomach cancer/colon cancer human colon cancer ht-num2 fibrosarcoma htnum4 stomach cancer mknnum2 cell cultur absenc glucos presenc glucos upr-induc chemic stressor n-glycosyl inhibitor tunicamycin calcium ionophor anum5 hypoglycemia-mimick agent num-deoxyglucos 2dg,0,1.0,0.0,789
85,morphin postop pain compar effect iv acetaminophen oral ibuprofen respect postop pain control morphin requir patient receiv morphin patient-control iv analgesia pcia cesarean deliveri,0,1.0,0.0,1702
86,clopidogrel stemi long-term cost-effect clopidogrel stemi patient,0,1.0,0.0,1127
87,gadolinium ms. four double-blind trial relapsing-remit ms demonstr ivig may reduc relaps rate progress number gadolinium-enhanc lesion,0,1.0,0.0,1807
88,sorafenib papillari thyroid carcinoma success use sorafenib treat pediatr papillari thyroid carcinoma,0,1.0,0.0,140
89,propofol myocardi injuri specif hypothes ripc isofluran anesthesia attenu myocardi injuri patient undergo coronari arteri bypass graft cabg surgeri effect may differ propofol anesthesia,0,1.0,0.0,485
90,cadmium hypertens addit blood lead mercuri cadmium covari not affect associ blood mn preval hypertens,0,1.0,0.0,2454
91,aspirin atrial fibril compar studi efficaci coumadin aspirin primari cardioembol stroke prevent chronic rheumat heart diseas mitral stenosi atrial fibril conduct siriraj hospit mahidol univers bangkok thailand,0,1.0,0.0,2936
92,testosteron obes known bmi invers proport serum total testosteron concentr low serum shbg level obes contribut low serum total testosteron,0,1.0,0.0,448
93,carvedilol ad mous present evid chronic oral administr carvedilol nonselect e_-adrenerg receptor blocker significantli attenu brain oligomer e_-amyloid content cognit deterior num independ ad mous model,0,1.0,0.0,3061
94,methadon hepat c. low risk hepat c seroconvers methadon mainten treatment,0,1.0,0.0,308
95,theophyllin asthmat nineteen asthmat subject given num3 mg sustained-releas theophyllin prepar twice daili num week,0,1.0,0.0,1808
96,vancomycin rp vitro antistaphylococc activ rp num5 new streptogramin compar vancomycin teicoplanin against staphylococcu aureu rp num5 activ agent against coagulase-neg staphylococci,0,1.0,0.0,503
97,tzd diabet furthermor incid anemia end reach num group tzd num2 group acei/arb/tzdnumcoadministr ra inhibitor ppar-e_ agonist consid differenti diagnosi hematocrit lower anemia uncompl type num diabet patient normal serum creatinin,0,1.0,0.0,277
98,phenytoin pht pharmacoresist epilept patient may ascrib least two not mutual exclus mechan pharmacokinet mechan decreas sensit avail target antiepilept drug a i.e. carbamazepin phenytoin cbz pht,0,1.0,0.0,2384
99,ozon t2dm/type num diabet mellitu examin whether short-term exposur air pollut fine particl ozon heat result perturb arteri blood pressur bp person type num diabet mellitu t2dm,0,1.0,0.0,332
100,indomethacin respiratori distress syndrom antenat indomethacin not associ intraventricular hemorrhag patent ductu arteriosu respiratori distress syndrom bronchopulmonari dysplasia mortal,0,1.0,0.0,2670
101,testosteron obes review describ relationship low serum testosteron concentr ed obes patient metabol syndrom type num diabet mellitu,0,1.0,0.0,2436
102,sodium nitroprussid hemolysi cardiac surgeri may increas risk cyanid toxic hemolysi cardiopulmonari bypass cpb may catalyz releas free cyanid sodium nitroprussid,0,1.0,0.0,815
103,alcohol alcohol abus patient secondari rmr like alcohol abus p numnum2 hiv-coinfect p numnum2,0,1.0,0.0,845
104,progesteron tumour estrogen progesteron receptor er pr immunocytochem analys mammari tumour cell obtain fine needl sampl num2 patient,0,1.0,0.0,2374
105,heparin harp harp found differ effect neutral anticoagul activ mimet heparan sulphat otrnum4 heparin purifi system human plasma,0,1.0,0.0,2070
106,fatti acid hyperemia endotheli function measur reactiv hyperemia use strain-gaug plethysmographi compar serum level fatti acid metabolit,0,1.0,0.0,930
107,calyculin a. breast cancer revers phase phosphoprotein array analysi reveal increas phosphoryl num out num2 ser/thr phosphosit indic select inhibit phosphatas calyculin a. calyculin treatment induc cell cycl arrest mda-mb-num3 mcf-num breast cancer cell,0,0.7875,0.2125,354
108,glucos ovarian cancer show epitheli ovarian cancer cell highli sensit glucose-deprivation-induc cell death like resveratrol glucos depriv induc caspase-independ cell death hallmark autophagi,0,0.7981,0.2019,1425
109,acetazolamid cataract studi evalu effect acetazolamid latanoprost travoprost bimatoprost brimonidin brinzolamid timolol pain phacoemulsif cataract surgeri,0,1.0,0.0,688
110,azt infect interestingli surviv prolong greater treatment start five two year infect no strike increas surviv time dose azt inhibit num2 hiv prolifer use instead lower one induc num2 inhibit,0,1.0,0.0,2114
111,pioglitazon type object prevent programm studi whether combin pioglitazon lifestyl modif would enhanc efficaci lifestyl modif prevent type num diabet asian indian impair glucos toler,0,1.0,0.0,1861
112,alfuzosin benign prostat hyperplasia evalu effect alfuzosin num2 mg daili administ num year progress event men lower urinari tract symptoms/benign prostat hyperplasia luts/bph,0,1.0,0.0,1505
113,atra/all-tran retino acid cytotox pretreat myeloid leukemia line hl-num2 all-tran retino acid atra up-regul aqp9 lead significantli increas arsen uptak as2o3-induc cytotox incub as2o3 might explain synerg atra as2o3,0,0.7897,0.21030000000000004,2143
114,estrogen tumor/breast cancer previous demonstr inactiv retinoblastoma protein prb famili tumor suppressor caus antiestrogen resist mcf-num cell wide studi model estrogen respons human breast cancer,0,0.6239,0.3761,733
115,anum5 hypoglycemia human colon cancer ht-num2 fibrosarcoma htnum4 stomach cancer mknnum2 cell cultur absenc glucos presenc glucos upr-induc chemic stressor n-glycosyl inhibitor tunicamycin calcium ionophor anum5 hypoglycemia-mimick agent num-deoxyglucos 2dg,0,1.0,0.0,484
116,gaba brain ischemia similar alter abund gaba r subunit observ vivo brain ischemia,0,1.0,0.0,58
117,curcumin ovarian cancer data indic er stress autophagi may play role apoptosi induc curcumin analogu bnum2 epitheli ovarian cancer cell line autophagi inhibit increas curcumin analogue-induc apoptosi induc sever er stress,0,0.7939,0.20609999999999995,337
118,sunitinib renal cell carcinoma cost-effect evalu sunitinib first-lin target therapi metastat renal cell carcinoma spain,0,1.0,0.0,2297
119,pregabalin neuropath pain aim studi evalu toler safeti efficaci pregabalin indian patient peripher neuropath pain,0,1.0,0.0,2357
120,tunicamycin hypoglycemia human colon cancer ht-num2 fibrosarcoma htnum4 stomach cancer mknnum2 cell cultur absenc glucos presenc glucos upr-induc chemic stressor n-glycosyl inhibitor tunicamycin calcium ionophor anum5 hypoglycemia-mimick agent num-deoxyglucos 2dg,0,1.0,0.0,1049
121,"num num'-oligoadenyl chronic leukemia ten patient hairi cell leukemia hcl seven patient b-cell chronic leukemia bcl studi intracellular num num'-oligoadenyl synthetas num,5oa activ mononuclear cell num h num2 h num2 h pentostatin administr",0,1.0,0.0,695
122,imatinib cmd imatinib mesyl gleevec small molecul inhibitor abl kit platelet-deriv growth factor receptor pdgfr tyrosin kinas report effect treatment hypereosinophil syndrom he rare eosinophilia-associ chronic myeloid disord eos-cmd character num num2 qnum2 pnum2 cytogenet abnorm,0,1.0,0.0,863
123,resveratrol ovarian cancer show epitheli ovarian cancer cell highli sensit glucose-deprivation-induc cell death like resveratrol glucos depriv induc caspase-independ cell death hallmark autophagi,0,0.7921,0.2079,315
124,nitroglycerin myocardi infarct current guidelin call nitroglycerin prescrib patient coronari heart diseas includ stabl angina recov acut coronari syndrom myocardi infarct,0,1.0,0.0,2064
125,aspirin atrial fibril active-w atrial fibril clopidogrel trial irbesartan prevent vascular event studi demonstr warfarin superior platelet therapi clopidogrel plu aspirin prevent af embol event,0,0.8140000000000001,0.18599999999999994,2565
126,num-fluorouracil toxic feasibl toxic local respons rate intra-arteri chemotherapi num-fluorouracil epirubicin mitomycin patient num2 year local advanc breast cancer evalu,0,0.7948,0.20520000000000005,1301
127,capecitabin rectal cancer patient t3/t4 node posit rectal cancer treat capecitabin num num3 mg/m num twice daili bid day num-num2 irinotecan num3 mg/m num day num everi num2 day num cycl follow capecitabin num3 mg/m num bid day num-num per week concurr radiotherapi num2num gy num2 fraction,0,1.0,0.0,2537
128,camp asthma varieti drug known act via increas intracellular camp use treatment asthma,0,1.0,0.0,1758
129,quinin poison case ocular toxic vasospasm secondari quinin poison describ,0,0.6163,0.3837,648
130,curcumin gastric carcinoma curcumin biolog activ compound rhizom curcuma longa could inhibit cell growth induc apoptosi gastric carcinoma,0,0.6214,0.3786000000000001,2620
131,batimastat cancer batimastat bb-num2 first inhibitor class enter clinic trial cancer patient,0,1.0,0.0,105
132,glucos glucos intoler furthermor drug link develop glucos intoler thu import monitor bodyweight fast blood glucos frequent basi,0,1.0,0.0,795
133,met5 enkephalin colon cancer opioid growth factor met5 enkephalin prevent incid retard growth human colon cancer,0,1.0,0.0,329
134,olmesartan medoxomil hypertens efficaci toler olmesartan medoxomil combin amlodipin patient moder sever hypertens amlodipin monotherapi random double-blind parallel-group multicentr studi,0,1.0,0.0,2339
135,ramipril adpkd forty-six hypertens adpkd patient random either ramipril n num2 metoprolol n num2,0,1.0,0.0,1951
136,thiobarbitur asthmat asthmat patient num2 num2 num2 mean num2 confid interv receiv thiobarbitur num2 num num2 receiv oxybarbitur none num num2 receiv propofol wheez intub,0,1.0,0.0,658
137,nickel hyperlipidemia accord multivari analysi signific predictor cr-isr refer vessel diamet p=.num4 follow nickel-posit p=.num4 hyperlipidemia p=.num4,0,1.0,0.0,2289
138,polyethylen glycol ada deficiency/adenosin deaminase/ada polyethylen glycol-conjug adenosin deaminas ada therapi provid temporari immun reconstitut child delayed-onset ada defici,0,1.0,0.0,1877
139,enzalutamid ar resist enzalutamid abirateron howev mark return ar signal indic remark addict prostat cancer cell ar pathway,0,0.8037,0.19630000000000009,2779
140,simvastatin pad pad patient major coronari event occur fewer patient atorvastatin group num2num simvastatin group num2num differ not reach statist signific,0,1.0,0.0,2502
141,vancomycin visa mutant display reduc vancomycin daptomycin suscept phenotyp alter eg thicker cell wall abnorm autolysi typic vivo visa mutant,0,1.0,0.0,578
142,naproxen rheumatoid arthriti addit effect combin naproxen paracetamol rheumatoid arthriti,0,0.626,0.374,2258
143,sumatriptan migrain sinc vasoconstrictor respons sumatriptan reproduc outsid migrain attack action appear direct vascular effect not indirectli mediat via neural mechan,0,1.0,0.0,404
144,no cf median j no br significantli lower cf adult healthi control numnum2 nl/ rang numnum2-numnum2 vs. numnum2 nl/ numnum2-numnum2 p numnum3 median c alv similar group num ppb num-num vs. num num-num,0,1.0,0.0,2574
145,loratadin chamber regul humid particip evalu cae chamber regul humid temperatur airflow visual task baselin take num2 mg either loratadin cetirizin hydrochlorid daili num day,0,0.8092,0.1908,2822
146,efv/efavirenz death analyz progress death caus aid death aids/death compar efavirenz efv nevirapin nvp nelfinavir idinavir ritonavir rtv rtv-boost proteas inhibitor pi saquinavir abacavir,0,1.0,0.0,2412
147,corticosteroid eosinophil infiltr myocardi biopsi reveal eosinophil infiltr degranul cardiogen shock revers prompt institut corticosteroid therapi,0,1.0,0.0,2570
148,pravastatin non-insulin-depend diabet mellitus/niddm multin num2-week random double-blind placebo-control studi evalu efficaci safeti low-dos pravastatin num3 patient non-insulin-depend diabet mellitu niddm hypercholesterolemia serum total cholesterol concentr num-num mmol/l num3 num3 mg/dl,0,1.0,0.0,1697
149,levothyroxin hypothyroid effect levothyroxin total lipid profil assess analyt capillari isotachophoresi patient hypothyroid,0,1.0,0.0,1645
150,num-fluorouracil colorect cancer oxaliplatin weekli bolu num-fluorouracil leucovorin pretreat advanc colorect cancer patient phase ii studi,0,1.0,0.0,254
151,methylprednisolon leukem differenti contrast methylprednisolon no effect phosphatas inhibitor num num -induc leukem differenti,0,1.0,0.0,2385
152,nitric oxid toxic addit low toxic gossypol thioderiv revers nitric oxid donor physiolog media,0,0.7969,0.20309999999999995,1762
153,aspirin respiratori diseas studi aim identifi prognost factor aspirin-exacerb respiratori diseas compar clinic genet data clinic cours,0,0.6079,0.3921,2153
154,otrnum4 harp harp shown compet antithrombin thrombin bind heparin otrnum4 respect,0,1.0,0.0,2081
155,ramosetron corticotropin releas factor/crf ramosetron num num3 microg/kg pnumo found significantli suppress abnorm defec induc conditioned-fear stress cf restraint stress corticotropin releas factor crf num-ht rat mice effect potent alosetron cilansetron loperamid,0,0.6029,0.3971,2415
156,alcohol viral hepat includ requir improv enzymolog screen despit introduct test hepat c imbal popular unexplain chronic aminotransferas elev effort solv inher problem inadequ attempt use metabol chang hepatocyt improv diagnosi prognosi pathophysiolog understand viral liver diseas remark investig num'-num'-oligoadenyl synthetas better control interferon therapi chronic viral hepat use enzym marker etiolog particularli detect alcohol induc liver diseas continu prefer aminotransferas scenario although ratio aspart aminotransferas alanin aminotransferas mitochondri aspart aminotransferas total aspart aminotransferas activ larg depend sever intralobular local damag stage liver diseas,0,1.0,0.0,2650
157,glucos glucos intoler three criteria metabol syndrom high triglycerid level glucos intoler obes fulfil three subject numnum2,0,1.0,0.0,2876
158,gaba asthma critic role solut carrier famili num neurotransmitt transport betaine/gaba member num2 slc6anum2 gene gabaerg transmiss associ mucu product asthma make candid gene aia associ studi,0,0.7982,0.2018,88
159,glutathion head neck squamou carcinoma chemosensit head neck squamou carcinoma cell line not primarili correl glutathion level modifi glutathion deplet,0,1.0,0.0,713
160,thiazid angina calcium channel blocker ccb attract altern thiazid patient uncontrol intoler thiazid specif indic agent eg angina sever diastol dysfunct,0,0.7992,0.2008,2846
161,csa/cyclosporin arthriti methotrex mtx sulfasalazin ssz cyclosporin csa wide use dmard treatment psa safe effect patient activ peripher arthriti although not appear effect axial manifest,0,1.0,0.0,2604
162,sorbitol lactic acidosi propos mechan type b lactic acidosi relat metabol sorbitol,0,0.6131,0.3869,2933
163,bupivacain pain bupivacain morphin unlik entonox produc lower pain score associ drain remov,0,0.7944,0.2056,2582
164,etomid depress retrospect comparison effect propofol etomid stimulu variabl efficaci electroconvuls therapi depress inpati,0,1.0,0.0,812
165,aspirin ischem stroke post-hoc analysi num random ischem stroke trial aspirin treatment failur not found associ increas risk recurr stroke death,0,1.0,0.0,1748
166,dichlorphenamide/dcp hypopp/hypokalem period paralysi one studi dichlorphenamid dcp vs placebo test two group particip num2 hypokalem period paralysi hypopp num2 hyperkalem period paralysi hyperpp base clinic criteria,0,1.0,0.0,97
167,pge2/prostaglandin e2 tumor necrosi factor-a/tnfa plasma concentr interleukin-1b il-1b thromboxan b2 txb2 prostaglandin e2 pge2 tumor necrosi factor-a tnfa measur enzyme-link immunosorb assay elisa techniqu,0,1.0,0.0,839
168,rivastigmin alzheim 's diseas drug use treat alzheim 's diseas includ acetyl cholinesteras inhibitor achi donepezil rivastigmin galantamin nmda receptor antagonist memantin,0,1.0,0.0,366
169,pimecrolimu atop dermatitis/ad previou studi suggest earli intervent pimecrolimu cream num first sign and/or symptom relaps atop dermat ad follow remiss may prevent occurr sever flare therefor reduc corticosteroid exposur long term,0,1.0,0.0,2927
170,hva drug action howev administr dopamin postsynapt antagonist expect increas synapt dopamin avail therebi increas hva concentr accord tradit model drug action,0,1.0,0.0,1053
171,estrogen breast cancer target vascular endotheli growth factor vegf estrogen receptor er signal pathway concomitantli may provid enhanc therapeut benefit er-posit breast cancer,0,1.0,0.0,343
172,fluoxetin postnat depress women postnat depress effect treat fluoxetin effect cours cognitive-behaviour counsel short-term,0,1.0,0.0,128
173,clonidin pmdd/premenstru dysphor disord women meet strict criteria premenstru dysphor disord pmdd examin whether clonidin alpha2-adrenerg receptor ar agonist would differ effect sexual abus versu non-abus pmdd women measur autonom nervou system function,0,1.0,0.0,3029
174,capsaicin thermal hyperalgesia investig effect guanethidin pretreat thermal hyperalgesia experiment site sensit heat topic applic num capsaicin,0,0.8179,0.18210000000000004,1091
175,borrelidin angiogenesi use improv model confirm tnp-num3 well-known inhibitor borrelidin antibiot streptomyc rochei significantli inhibit widr cell-induc angiogenesi,0,1.0,0.0,2799
176,pravastatin hyperlipidemia sinc hyperlipidemia not improv pravastatin atorvastatin niceritrol sinc level thyroid-stimul hormon tsh free t4 num3 iu/ml num ng/dl respect patient diagnos secondari hyperlipidemia hypothyroid,0,0.8245,0.1755,2101
177,capecitabin tumor phase studi conduct primarili determin maximum toler dose mtd tesetaxel novel oral activ semisynthet microtubul inhibitor taxan class administ oral capecitabin patient advanc solid tumor,0,1.0,0.0,2419
178,imatinib gist/gastrointestin stromal tumour although tyrosin kinas inhibitor imatinib shown activ agent patient gastrointestin stromal tumour gist complet remiss almost never seen patient final experi diseas progress cours treatment,0,0.6029,0.3971,687
179,trichostatin a/tsa inflamm examin effect histon deacetylas inhibitor trichostatin tsa behavior macrophag subconjunctiv fibroblast vitro ocular surfac inflamm scar vivo use alkali burn wound heal model,0,0.7977,0.20230000000000006,55
180,amiodaron af short-term studi dronedaron less effect amiodaron decreas af recurr better safeti profil specif regard thyroid neurolog event lack interact oral anticoagul,0,1.0,0.0,1521
181,cisplatin small cell lung cancer present studi aim determin whether erk1/num akt pathway contribut cisplatin resist human small cell lung cancer anum3 cell,0,1.0,0.0,3081
182,sunum4 tripl combin tripl combin use low-tox drug exposur pemetrex sunum4 result greater respons treatment alon combin two modal test endotheli tumor cell model,0,1.0,0.0,513
183,poly-sno-hsa tumor observ pegyl enhanc stabil poly-sno-hsa vitro vivo dimer poly-sno-hsa enhanc antitumor activ via effici deliveri no colon num2 tumor-bear mice,0,1.0,0.0,2254
184,mitomycin c. tumor reductas enzym express across nation cancer institut tumor cell line panel correl sensit mitomycin c eo9,0,1.0,0.0,2336
185,spiperon schizophrenia 3h-spiperon bind lymphocyt neuroleptic-naive-schizophrenia effect neurolept treatment,0,1.0,0.0,2889
186,clozapin blood glucos accumul data develop glucos intoler adult receiv clozapin closer monitor bodyweight fast blood glucos imper,0,0.8041,0.1959,2379
187,saquinavir death analyz progress death caus aid death aids/death compar efavirenz efv nevirapin nvp nelfinavir idinavir ritonavir rtv rtv-boost proteas inhibitor pi saquinavir abacavir,0,1.0,0.0,2086
188,paliperidon schizophrenia paliperidon er potenti offer advantag parent compound second gener agent may aid ensur complianc among person schizophrenia,0,1.0,0.0,3072
189,telmisartan cardiovascular diseas present studi suggest due delta lock structur telmisartan may superior arb halt cardiovascular diseas patient hypertens,0,1.0,0.0,1383
190,terazosin hypertens total num2 num3 patient hypertens evalu num4 primari commun care facil num4 patient not treat previous hypertens num4 switch terazosin anoth antihypertens agent num4 receiv terazosin addit agent not control hypertens,0,1.0,0.0,54
191,glucos type rosiglitazon significantli increas glucos uptak wild-typ podocyt associ transloc glut1 plasma membran,0,1.0,0.0,3069
192,capecitabin toxic design studi local advanc rectal cancer determin patholog respons toxic disease-fre surviv df induct capecitabin plu irinotecan follow capecitabine-bas chemoradiotherapi crt analyz gene express enzym involv metabol capecitabin irinotecan associ respons toxic,0,1.0,0.0,2826
193,sugammadex major depress rocuronium-sugammadex reduc myalgia headach electroconvuls therapi patient major depress,0,1.0,0.0,576
194,yohimbin ptsd metabol tend decreas patient ptsd increas healthi subject follow administr yohimbin,0,1.0,0.0,1223
195,glucos tumor/tumor glucos depriv featur poorli vascular solid tumor activ unfold protein respons upr stress-sign pathway tumor cell,0,0.8299,0.17010000000000006,938
196,aldosteron wast infection-trigg life-threaten salt-loss hyperkalaemia develop two male infant wast inappropri low plasma aldosteron concentr elev plasma renin activ,0,0.8205,0.1795,2974
197,capecitabin tumour/breast cancer effect capecitabin vinorelbin cell prolifer metabol cox2 pnum2 express breast cancer cell line solid tumour tissu,0,0.6017,0.3983,2222
198,cyclosporin ibd four case nhl ibd cohort sir num2num num2 ci num-num2 p=numnum4 receiv immunosuppress therapi azathioprin n=num methotrex n=num methotrex cyclosporin n=num,0,0.8062,0.1938,2528
199,ketanserin contract ketanserin num2-num4 nm antagon part num-ht-induc contract,0,0.8188,0.18120000000000008,2041
200,tryptophan bipolar affect disord clinic neurochem effect acut tryptophan deplet unaffect rel patient bipolar affect disord,0,1.0,0.0,1378
201,triiodothyronin major depress disord open studi triiodothyronin augment select serotonin reuptak inhibitor treatment-resist major depress disord,0,1.0,0.0,2256
202,oestrogen menstrual bleed randomis control trial progestogen via rout alon combin oestrogen treatment irregular menstrual bleed associ oligo/anovul,0,1.0,0.0,2734
203,glucos impair glucos toler pioglitazon not enhanc effect lifestyl modif prevent convers impair glucos toler diabet asian indian result indian diabet prevent programme-num idpp-num,0,1.0,0.0,1648
204,num-ht contract ring intact endothelium num-ht1-like-select agonist sumatriptan caus small contract -log ecnum2 num intrins activ numnum2 respect num-ht resist blockad num4 nm ketanserin antagon num3 nm methiothepin,0,1.0,0.0,1422
205,dapson angioedema num2-year-old woman num yr histori chronic recurr urticari vascul angioedema refractori convent treatment includ glucocorticosteroid h1 h2 blocker nonsteroid antiinflammatori agent methotrex hydroxychloroquin dapson azathioprin intraven gamma globulin plasma exchang success treat interferon alpha 2a,0,1.0,0.0,2475
206,epirubicin hcc/hepatocellular carcinoma pharmacokinet clinic activ epirubicin investig num2 patient hepatocellular carcinoma hcc receiv epirubicin num2 mg/m2 drug given intraven num patient via hepat arteri num patient num also underw embolis,0,1.0,0.0,2171
207,feiba thrombot recombin factor viia rfviia increasingli use altern feiba howev thrombot safeti profil rfviia remain incomplet character,0,1.0,0.0,353
208,dexamethason tumor stimul primari human corneal epitheli cell keratocyt retin endotheli cell num num2 ng/ml interleukin 1e_ il-1e_ result signific increas numer inflammatori cytokin includ il-num il-num tumor necrosi factor e tnf-e dexamethason abl significantli inhibit effect,0,1.0,0.0,507
209,lidocain pain fibromyalgia impact questionnair fiq health assess questionnair visual analog scale va pain appli first lidocain infus immedi fifth infus num2 day fifth infus,0,0.6101,0.3899,1336
210,fluconazol infect clinic trial report support use fluconazol treatment candidiasi particularli oropharyng esophag infect immunocompromis host,0,1.0,0.0,2812
211,acebutolol lupu erythematosu although first report acebutolol-induc scle awar occurr avoid acebutolol recommend patient stigmata lupu erythematosu,0,0.8011,0.1989,2257
212,thiopent asthmat wherea thiopent contract human isol bronchi propofol etomid reduc histamine-induc contract human isol airway smooth muscl either not sensit passiv sensit asthmat serum,0,1.0,0.0,2026
213,glucos oral glucos toler fast glucos insulin lipid lipoprotein profil oral glucos toler insulin secret insulin-medi glucos dispos hyperglycem clamp bodi composit dual energi x-ray absorptiometri determin lopinavir/ritonavir administr,0,0.799,0.201,1981
214,yohimbin ptsd signific differ brain metabol respons yohimbin patient ptsd compar healthi subject prefront tempor pariet orbitofront cortex,0,1.0,0.0,534
215,metformin diabet metformin use among individu risk type num diabet,0,1.0,0.0,1734
216,ribavirin diabet mellitu perform proteom analysi liver specimen num2-year-old woman affect hepat c genotyp 1a alcohol diabet mellitu type num antivir treatment pegyl interferon alpha 2b ribavirin,0,1.0,0.0,2088
217,docetaxel hypox given doxorubicin docetaxel th-num3 complement enhanc anticanc effect perivascular hypox region also increas toxic,0,1.0,0.0,1456
218,methamphetamin cannabi depend studi evalu role nac cocain depend three studi cannabi depend two studi nicotin depend two studi methamphetamin addict one studi patholog gambl one studi,0,1.0,0.0,1503
219,num num-dihydroxybenzaldehyd cancer concentr num3 microm num num-dihydroxybenzaldehyd caus num2 growth inhibit human cancer cell unum3,0,1.0,0.0,2360
220,gemcitabin refractori hodgkin 's diseas gemcitabin treatment relaps refractori hodgkin 's diseas,0,1.0,0.0,1372
221,tam/tamoxifen breast cancer/malign neoplasm recent studi shown antiestrogen tamoxifen tam use treatment malign neoplasm breast cancer,0,1.0,0.0,2963
222,dihydrotestosterone/dht ligand-bind domain/lbd prostat cancer pca therapi typic involv administr classic antiandrogen competit inhibitor androgen receptor ar ligand dihydrotestosteron dht testosteron te ligand-bind pocket lbp ligand-bind domain lbd ar,0,1.0,0.0,2871
223,titanium perin hernia repair describ applic titanium mesh perin hernia repair,0,1.0,0.0,1997
224,paliperidon palmit hallucin studi suggest risperidon long-act inject paliperidon palmit long-act inject may use treatment dd patient specif nonpromin hallucin,0,1.0,0.0,2665
225,corticosteroid cataract use intranas corticosteroid not associ increas risk cataract studi popul,0,1.0,0.0,2209
226,diltiazem hypertens relat rsnum5 statu num-month blood pressur reduct risk cardiovascular event num4 hypertens patient dbp num3 mmhg nordic diltiazem studi nordil random either e_-block and/or diuretic-bas treatment diltiazem-bas treatment,0,1.0,0.0,1083
227,sphingosin growth arrest inhibitor display k valu submicromolar rang sphingosin kinas cultur vascular smooth muscl cell decreas s1p level initi growth arrest,0,1.0,0.0,519
228,sfa lp lp lipopeptid contamin wide use reagent fatty-acid-fre bsa explain previous report stimul tlr2 tlr4 sfa,0,0.7874,0.2126,608
229,fatti acid hcv infect real time data confirm vivo human hcv infect pathway relat fatti acid glucos metabol free radic scaveng inhibit,0,0.7917,0.20830000000000004,2445
230,arginin vasopressin ocd abnorm csf arginin vasopressin corticotropin-releas hormon oxytocin somatostatin level report ocd,0,0.8103,0.1897,772
231,nicardipin hypertens effect calcium-entri blocker nicardipin intraren hemodynam essenti hypertens,0,0.7898,0.21020000000000005,2287
232,testosteron metabol syndrom characterist low serum testosteron concentr observ obes men also present men metabol syndrom type num diabet mellitu,0,1.0,0.0,732
233,piperacillin melioidosi role piperacillin/ tazobactam melioidosi remain undefin,0,1.0,0.0,1038
234,oxygen pain aural canal core skin surfac num2 site temperatur oxygen consumpt pain visual analogu score concentr epinephrin norepinephrin glucos cortisol lactat free fatti acid plasma measur epidur blockad num2 min epidur blockad end surgeri num h surgeri,0,1.0,0.0,1529
235,mannitol lactic acidosi report case hyperglycaemia lactic acidosi complic turp syndrom caus massiv absorpt approxim num2 litr sorbitol- mannitol irrig solut,0,0.8183,0.1817,2911
236,mangafodipir hepat lesion compar mangafodipir-enhanc magnet reson mr superparamagnet iron oxid spio -enhanc imag abil detect character focal hepat lesion,0,1.0,0.0,2328
237,thalidomid better toxic lenalidomid better toxic profil thalidomid,0,1.0,0.0,928
238,ibandron skelet complic intraven ibandron reduc incid skelet complic patient breast cancer bone metastas,0,1.0,0.0,2463
239,isofluran ripc ripc isofluran anesthesia n num2 decreas area ctni time curv ctni auc -num2 num3 num3 ng/ml num2 h vs. num3 num3 ng/ml num2 h p numnum3 peak num num ng/ml vs. num2num num p numnum3 serial p numnum3 postop ctni compar isofluran alon n num2,0,0.7865,0.2135,139
240,ribavirin hiv/hepat c virus-coinfect treatment pegyl interferon plu ribavirin safe effect hiv/hepat c virus-coinfect patient,0,1.0,0.0,2307
241,pimecrolimu ad num2-week random control studi conduct num3 patient age or=num2 year histori mild moder ad clear/almost clear diseas random pimecrolimu cream num n=num3 match vehicl cream n=num3,0,0.7894,0.2106,3084
242,clopidogrel stemi addit clopidogrel aspirin given num year set stemi highli cost-effect strategi,0,1.0,0.0,417
243,glucos diabet mellitu type studi closed-loop system control plasma glucos level patient diabet mellitu type num propos,0,1.0,0.0,1164
244,aminoglycosides/aminoglycosid tubular marker protein excret tubular marker protein enhanc combin administr cephalosporin aminoglycosid mainli due aminoglycosid compon,0,0.7975,0.2025,176
245,procaterol asthmat effect procaterol beta num-adrenoceptor agonist skin wheal respons caus inflammatori mediat asthmat children,0,1.0,0.0,796
246,potassium colorect cancer dietari intak retinol vitamin thiamin riboflavin vitamin b6 folat vitamin bnum2 vitamin calcium iron magnesium potassium n num fatti acid n num fatti acid ratio n num n num fatti acid estim associ colorect cancer examin use condit logist regress model adjust exact age height weight energi intak alcohol intak fiber intak smoke educ social class physic activ,0,0.8079999999999999,0.1920000000000001,1653
247,paracetamol analgesia twenti per cent diclofenac group num2 paracetamol group requir rescu analgesia not statist signific,0,1.0,0.0,2233
248,bile acid barrett 's esophagu aim studi assess express bile acid receptor esophagu normal esophag barrett 's esophagu adenocarcinoma investig possibl function,0,1.0,0.0,1969
249,sodium chlorid death patient random receiv sodium bicarbon vs sodium chlorid rate death dialysi myocardi infarct cerebrovascular event not differ significantli num2 day num vs num num vs num num vs num num vs num respect num2 day num month num vs num num vs num num vs num num vs num respect p .num2,0,0.8042,0.1958,1707
250,desmopressin nocturia open in-pati increment safeti efficaci studi desmopressin women multipl sclerosi nocturia,0,0.8042,0.1958,2246
251,amphotericin b. viscer leishmaniasi liposom amphotericin b effect safe altern treatment viscer leishmaniasi indian subcontin,0,1.0,0.0,223
252,arb type furthermor incid anemia end reach num group tzd num2 group acei/arb/tzdnumcoadministr ra inhibitor ppar-e_ agonist consid differenti diagnosi hematocrit lower anemia uncompl type num diabet patient normal serum creatinin,0,1.0,0.0,295
253,sulfamethoxazol wegen 's granulomatosi long-term sulfamethoxazole-trimethoprim wegen 's granulomatosi,0,0.8065,0.1935,3
254,artemisinin cardiotox contrast artemisinin not reveal cardiotox,0,1.0,0.0,1971
255,aspirin ischem stroke object determin aspirin treatment failur predict recurr ischem stroke and/or death,0,1.0,0.0,607
256,alcohol prostat cancer alcohol drink unrel prostat cancer risk,0,0.8158,0.18420000000000009,878
257,indomethacin coma includ 'forc hyperventil paco2 num2 mmhg barbitur coma experiment protocol tri buffer indomethacin induc hypothermia,0,1.0,0.0,879
258,glucos stomach cancer/colon cancer human colon cancer ht-num2 fibrosarcoma htnum4 stomach cancer mknnum2 cell cultur absenc glucos presenc glucos upr-induc chemic stressor n-glycosyl inhibitor tunicamycin calcium ionophor anum5 hypoglycemia-mimick agent num-deoxyglucos 2dg,0,1.0,0.0,1215
259,lopinavir/ritonavir oral glucos toler fast glucos insulin lipid lipoprotein profil oral glucos toler insulin secret insulin-medi glucos dispos hyperglycem clamp bodi composit dual energi x-ray absorptiometri determin lopinavir/ritonavir administr,0,0.7892,0.2108,428
260,perindopril arteriosclerosi present studi evalu effect treatment calcium channel blocker amlodipin angiotensin i-convert enzym inhibitor perindopril vascular endotheli function arteriosclerosi patient essenti hypertens alreadi receiv angiotensin receptor blocker monotherapi,0,1.0,0.0,1430
261,suramin metastat cancer suramin serum insulin-lik growth factor level metastat cancer patient,0,0.8217,0.1783,2718
262,panton-valentin leukocidin tissu infect studi investig outcom therapi without appropri antibiot among children ca-mrsa skin soft tissu infect ssti analyz outcom manag among children panton-valentin leukocidin pvl -posit strain pvl-neg strain,0,1.0,0.0,466
263,poly-sno-hsa tumor previous demonstr poly-nitr oxid no conjug human serum albumin poly-sno-hsa potenti dd carrier capabl accumul no tumor,0,0.8024,0.1976,2296
264,fluticason bronchiectasi cochran airway group rct regist cochran control clinic trial regist search use follow search term bronchiectasi corticosteroid* beclomethason budesonid fluticason triamcinolon flunisolid,0,1.0,0.0,619
265,zidovudine/zdv hiv-infect babi hiv-infect women randomis birth receiv singl dose nevirapin nvp alon zidovudin zdv twice daili week,0,1.0,0.0,221
266,sodium bicarbon nephropathi sodium bicarbon vs sodium chlorid prevent contrast medium-induc nephropathi patient undergo coronari angiographi random trial,0,0.8186,0.1814,1343
267,pioglitazon impair glucos toler pioglitazon not enhanc effect lifestyl modif prevent convers impair glucos toler diabet asian indian result indian diabet prevent programme-num idpp-num,0,1.0,0.0,152
268,ziprasidon multipl neurocognit domain robust find signific across multipl neurocognit domain adjac snp show evid associ rsnum5 ehf gene p-valu numnum2 num2 -num q-valu numnum3 mediat effect ziprasidon vigil rsnum5 slcnum2a9 p-valu num num2 -num q-valu numnum3 mediat effect olanzapin process speed rsnum5 il1a p-valu numnum2 num2 -num q-valu numnum3 mediat effect olanzapin work memori,0,1.0,0.0,535
269,oestrogen breast cancer effect transform growth factor beta num oestrogen metabol mcf-num breast cancer cell line,0,0.7983,0.2017,1799
270,methadon hydrochlorid overdos methadon hydrochlorid may increas risk lethal respiratori depress relat accident overdos life-threaten ventricular arrhythmia,0,0.6184,0.3816000000000001,922
271,naloxon respiratori depress patient experi opioid-rel toxic associ respiratori depress treat immedi opioid antagonist naloxon close monitor least num2 hour,0,1.0,0.0,515
272,ascorb acid dermat administr exogen ascorb acid advoc therefor treatment system chromium poison chromium dermat enhanc extracellular reduct chromium vi less bioavail chromium iii,0,1.0,0.0,131
273,hydroxychloroquin dmard establish dmard sulfasalazin hydroxychloroquin also demonstr efficaci use togeth methotrex,0,1.0,0.0,2692
274,iron defici iron vitamin defici impact anemia immun system,0,1.0,0.0,367
275,naltrexon psychiatr disord naltrexon disulfiram patient alcohol depend comorbid psychiatr disord,0,0.8055,0.1945,2716
276,num-hc tumor data suggest clonal abnorm observ posttranspl best explain clinic relaps tumor ex vivo marrow purg num-hc not like induc clonal chromosom abnorm normal cell,0,1.0,0.0,1141
277,ketamin analgesia doubl blind cross studi design evalu effect ketamin spinal morphin analgesia termin cancer pain patient,0,0.7963,0.2037,581
278,mannitol acut stroke mannitol use acut stroke case fatal num2 day num year,0,1.0,0.0,2489
279,doxycyclin furcat defect regener degre ii furcat defect num doxycyclin hyclat bioabsorb barrier,0,0.6007,0.3993,1225
280,vitamin d. chronic renal diseas influenc uv irradi vitamin metabol children chronic renal diseas,0,1.0,0.0,2866
281,cloretazin lymphoma anti prolif activ elaci cp-num4 combin cloretazin vnpnum5m idarubicin gemcitabin irinotecan topotecan human leukemia lymphoma cell,0,1.0,0.0,310
282,no migrain sinc calcineurin inhibitor known influenc renal metabol no key molecul tension-typ headach migrain interest whether calcineurin inhibitor might chang no metabol hbmec well,0,1.0,0.0,1034
283,cholesterol diabet aim studi examin effect max epa commerci avail fish oil prepar serum cholesterol lipoprotein apolipoprotein insulin-depend diabet iddm men dosag like accept patient,0,1.0,0.0,2930
284,clozapin extrapyramid symptoms/ep unlik clozapin receptor interact profil lend toward increas risk extrapyramid symptom ep hyperprolactinaemia,0,0.6191,0.3809,2852
285,atp primari tumor herein assess role syk-depend tonic bcr surviv signal dlbcl cell line primari tumor evalu efficaci atp-competit inhibitor syk rnum3 vitro,0,1.0,0.0,1519
286,rasagilin pd rasagilin shown effect monotherapi earli pd adjunct dopaminerg therapi,0,1.0,0.0,1076
287,busulfan medulloblastoma tumor includ childhood high-grad glioma d-num3 mg d-num3 mg adult high-grad glioma d-num2 mg d-num3 mg medulloblastoma dnum3 med dnum3 med ependymoma dnum3 ep dnum3 ep rhabdomyosarcoma te-num3 well sublin demonstr resist busulfan d-num3 mg br cyclophosphamid te-num3 cr procarbazin d-num3 mg pr melphalan te-num3 mr grow subcutan intracrani athym nude mice,0,1.0,0.0,1533
288,prostanoid pain brimonidin group exhibit lowest visual analog pain-scal score prostanoid especi bimatoprost group demonstr highest visual analog pain-scal score medianastandard deviat num0a1numnum2 num0a1numnum2 respect,0,0.8106,0.1894,11
289,fentanyl pain opioid rotat morphin fentanyl may effect allevi delirium pain cancer patient morphine-induc delirium,0,0.8113,0.1887,2902
290,oxygen aggress contrari might expect result suggest case aggress effort increas oxygen consumpt may detriment,0,1.0,0.0,2353
291,mangafodipir hepat lesion detect character focal hepat lesion mangafodipir vs. superparamagnet iron oxide-enhanc magnet reson imag,0,1.0,0.0,887
292,androgen ar/androgen receptor among androgen receptor splice variant ar-v particularli variant num ar-v7 implic resist enzalutamid abirateron preclin studi not target current avail ar-direct drug,0,1.0,0.0,1040
293,sodium coma taxin taxin b toxic alkaloid taxu block cardiac sodium calcium channel caus nausea vomit abdomin pain cardiac arrhythmia respiratori distress coma seizur death yew poison,0,0.6094,0.3906,1915
294,cyclosporin toxic although one larg random studi demonstr proven surviv advantag without increas toxic use cyclosporin inconsist result modul rais doubt util overal strategi use drug efflux blocker patient establish pgp overexpress,0,1.0,0.0,2953
295,thiazid hypertensive/hypertens thiazid diuret remain drug first choic treat hypertens african-american hypertens,0,1.0,0.0,2214
296,oxygen hypertens review focus vascular action reactiv oxygen speci role oxid stress vascular damag hypertens therapeut potenti modul oxygen radic bioavail hypertens,0,1.0,0.0,1346
297,pamidron bone pain repeat pamidron infus exert clinic relev analges effect half patient metastat bone pain,0,0.8111,0.1889,1228
298,methotrexate/mtx arthriti methotrex mtx sulfasalazin ssz cyclosporin csa wide use dmard treatment psa safe effect patient activ peripher arthriti although not appear effect axial manifest,0,1.0,0.0,259
299,amlodipin hypertens thirty-two patient essenti hypertens treat angiotensin receptor blocker monotherapi random receiv num mg amlodipin n=num2 num mg perindopril n=num2 daili morn num2 week,0,0.8212,0.17879999999999996,3027
300,metformin acut myocardi infarct chronic pretreat metformin associ reduct no-reflow phenomenon patient diabet mellitu primari angioplasti acut myocardi infarct,0,1.0,0.0,1901
301,raloxifen inflammatori result show tamoxifen raloxifen ici num3numnum3 induc anti-inflammatori respons acut model mous rat microgli cell,0,1.0,0.0,1231
302,heparan sulphat harp harp found differ effect neutral anticoagul activ mimet heparan sulphat otrnum4 heparin purifi system human plasma,0,1.0,0.0,505
303,glucos diabet mechan blood glucose-low effect num-day low calori diet vlcd num4 kj/d combin cessat blood glucose-low agent studi num2 num women num men obes bodi mass index num2num +/- num kg/m num mean +/- sem type num diabet patient age num2 +/- num year hba 1c num +/- num undergo insulin therapi,0,1.0,0.0,2431
304,midazolam statu epilepticu midazolam treatment acut refractori statu epilepticu,0,1.0,0.0,1801
305,clopidogrel st-elev myocardi infarction/stemi present single-cent longitudin cohort studi includ num num3 consecut patient st-elev myocardi infarct stemi undergo ppci pretreat num3 mg aspirin num3 mg clopidogrel,0,0.8211,0.17889999999999995,1585
306,nscnum5 ovarian cancer human ovarian cancer cell line coc1 cell treat differ nanomolar nscnum5 without cddp cell growth apoptosi evalu respect mtt assay annexin-v assay flow cytometri,0,1.0,0.0,2999
307,corticosteroid bronchiectasi bronchiectasi regular use inhal corticosteroid may improv lung function,0,1.0,0.0,2036
308,statin cvd investig effect high-dos versu usual-dos statin pre-specifi outcom pad incid addit perform posthoc analysi efficaci high-dos statin reduc cvd risk among patient pad,0,1.0,0.0,2904
309,verteporfin choroid neovascularization/cnv report outcom eye treat intravitr inject bevacizumab combin verteporfin photodynam therapi pdt choroid neovascular cnv age-rel macular degener amd,0,1.0,0.0,2366
310,bile acid adenocarcinoma aim studi assess express bile acid receptor esophagu normal esophag barrett 's esophagu adenocarcinoma investig possibl function,0,1.0,0.0,2105
311,olmesartan mbp amlodipine-olmesartan combin therapi bedtim administr reduc better mbp correct nocturn bp fall improv urinari albumin excret,0,1.0,0.0,2130
312,calcium hypertens conclus result suggest angiotensin i-convert enzym inhibitor perindopril superior calcium channel blocker amlodipin reduc vascular endotheli dysfunct co-administ angiotensin receptor blocker patient essenti hypertens,0,1.0,0.0,316
313,isofluran ripc thu ripc isofluran not propofol anesthesia decreas myocardi damag patient undergo cabg surgeri,0,0.805,0.19499999999999995,2226
314,ginsenosid rh2 ovarian cancer inhibitori effect oral administr ginsenosid rh2 growth human ovarian cancer cell nude mice,0,1.0,0.0,2498
315,arsen cytotox pretreat myeloid leukemia line hl-num2 all-tran retino acid atra up-regul aqp9 lead significantli increas arsen uptak as2o3-induc cytotox incub as2o3 might explain synerg atra as2o3,0,0.8011,0.1989,1262
316,atorvastatin hyperlipidemia sinc hyperlipidemia not improv pravastatin atorvastatin niceritrol sinc level thyroid-stimul hormon tsh free t4 num3 iu/ml num ng/dl respect patient diagnos secondari hyperlipidemia hypothyroid,0,1.0,0.0,2373
317,aspirin cardiac embol studi not support use aspirin primari prevent cardiac embol chronic rheumat heart diseas,0,1.0,0.0,1357
318,corticosteroid prostat cancer comprehens review peer review literatur perform topic secondari hormon therapi includ oral antiandrogen adren androgen inhibitor corticosteroid estrogen compound gonadotropin-releas hormon antagonist altern hormon therapi advanc prostat cancer,0,1.0,0.0,2416
319,num-fu adenocarcinoma nine human pancreat adenocarcinoma vari wide sensit chemotherapi especi num-fu,0,1.0,0.0,30
320,valdecoxib postop pain clinic trial demonstr efficaci safeti celecoxib rofecoxib postop pain preemptiv analgesia newer agent valdecoxib etoricoxib also demonstr efficaci set,0,1.0,0.0,2271
321,vorozol tumor vorozol like ovariectomi almost complet reduc tumor growth dmba-induc mammari carcinoma model rat,0,1.0,0.0,2494
322,coumadin mitral stenosi compar studi efficaci coumadin aspirin primari cardioembol stroke prevent chronic rheumat heart diseas mitral stenosi atrial fibril conduct siriraj hospit mahidol univers bangkok thailand,0,1.0,0.0,1277
323,kinum5 gastric cancer fgfr2 inhibitor kinum5 might therapeut promis treat drug-resist gastric cancer cell especi use combin snnum2 ptx vpnum2,0,1.0,0.0,204
324,num-fu cancer/colon cancer chloroquin potenti anti-canc effect num-fu colon cancer cell,0,1.0,0.0,617
325,metformin pco treatment insulin sensit metformin thiazolidinedion tzd improv metabol hormon pattern also improv ovul pco,0,1.0,0.0,488
326,ceftazidim neutropenia risk factor vre colon paediatr oncolog patient includ durat neutropenia durat antibiot therapi exposur ceftazidim amikacin teicoplanin number antibiot use,0,0.8108,0.18920000000000006,1658
327,borrelidin angiogenesi borrelidin also inhibit spontan lung metastasi bnum2-bl6 melanoma dose inhibit angiogenesi,0,0.7891,0.2109,2599
328,fludarabin cll/chronic lymphocyt leukemia base mechanist similar fludarabin cladribin success analogu treatment chronic lymphocyt leukemia cll hypothes clofarabin would effect indol leukemia,0,1.0,0.0,1496
329,indoxyl sulfat renal failur indoxyl sulfat progress renal failur effect low-protein diet oral sorbent indoxyl sulfat product urem rat undialyz urem patient,0,0.6076,0.3924,1950
330,aspirin stroke post-hoc analysi num random ischem stroke trial aspirin treatment failur not found associ increas risk recurr stroke death,0,1.0,0.0,2838
331,salicyl bronchial asthma drug choic patient not treat non-steroid anti-inflammatori drug nsaid peopl bronchial asthma peptic ulcer diseas hemophilia salicylate-sensit peopl children num2 year age pregnant breastfeed women,0,1.0,0.0,630
332,procaterol asthmat examin effect procaterol beta num-adrenoceptor agonist skin wheal respons histamin platelet-activ factor paf substanc p bradykinin eight asthmat children double-blind random cross-ov studi,0,1.0,0.0,1245
333,allylpyrocatechol rheumatoid arthriti taken togeth ex vivo studi establish allylpyrocatechol potent scaveng activ could consid add-on therapi treatment inflammation-associ disord like rheumatoid arthriti,0,1.0,0.0,2059
334,sorafenib renal cell carcinoma symptom hypothyroid occur num2 patient treat sorafenib due metastat renal cell carcinoma,0,0.805,0.19499999999999995,208
335,calcium hypertens effect calcium-entri blocker nicardipin intraren hemodynam essenti hypertens,0,0.8082,0.1918,2961
336,ketotifen artifici tear substitut comparison effect ketotifen fumar numnum3 olopatadin hcl num ophthalm solut season allerg conjunct num2-day random double-mask artifici tear substitute-control trial,0,1.0,0.0,2285
337,"pentostatin chronic leukemia ten patient hairi cell leukemia hcl seven patient b-cell chronic leukemia bcl studi intracellular num num'-oligoadenyl synthetas num,5oa activ mononuclear cell num h num2 h num2 h pentostatin administr",0,1.0,0.0,559
338,phenobarbit tonic-clon seizur num2-year-old man past histori gener tonic-clon seizur treat phenobarbit present spinocerebellar ataxia,0,0.8102,0.1898,345
339,cholesterol atherosclerosi conjug linol acid atherosclerosi no effect molecular marker cholesterol homeostasi thp-num macrophag,0,1.0,0.0,2989
340,ammonium citrat hepatocellular carcinoma human hepatocellular carcinoma cell line hep3b hepg2 combin lsnum3 ferric ammonium citrat lsnum3/feac inhibit hif-1 protein express not inhibit hif-1 mrna express,0,1.0,0.0,2243
341,mph adhd studi behavior physiolog action clinic behavior relev dose mph normal anim provid opportun explor role catecholamin transmitt prefront cortic function attent process relat normal oper brain circuit adhd patholog,0,1.0,0.0,2552
342,capecitabin hnscc tumor addit demonstr transgen express tp significantli enhanc tumoricid effect capecitabin hnscc tumor otherwis low endogen tp dpd ratio,0,0.802,0.19799999999999995,186
343,cocain cannabi depend studi evalu role nac cocain depend three studi cannabi depend two studi nicotin depend two studi methamphetamin addict one studi patholog gambl one studi,0,1.0,0.0,814
344,floxuridin tumour effect aberr hepat arteri anatomi tumour respons hepat arteri infus floxuridin colorect liver metastas,0,1.0,0.0,1458
345,methylprednisolon proteinuria surviv even prolong bindarit num medic diet combin low dose methylprednisolon num mg/kg inump partial modifi proteinuria surviv lupu mice addit group anim n num2,0,1.0,0.0,2983
346,salbutamol breathless respons regular inhal fenoterol ipratropium bromid meter dose inhal mdi larg volum spacer regular nebul salbutamol ipratropium bromid assess home peak flow record spirometri two subject score rate breathless simpl four-point scale b activ score st georg 's respiratori questionnair,0,1.0,0.0,1398
347,coumadin thromboembol compar studi coumadin aspirin primari cardioembol stroke thromboembol prevent chronic rheumat mitral stenosi atrial fibril,0,1.0,0.0,1632
348,bp bone diseas bp provid support care reduc rate skelet morbid evid not abolish criteria stop administr differ use classic antineoplast drug not stop metastat bone diseas progress,0,1.0,0.0,1246
349,rocuronium myalgia rocuronium-sugammadex reduc myalgia headach electroconvuls therapi patient major depress,0,1.0,0.0,1542
350,acetaminophen analgesia compar effect iv acetaminophen oral ibuprofen respect postop pain control morphin requir patient receiv morphin patient-control iv analgesia pcia cesarean deliveri,0,1.0,0.0,925
351,prednison diffus larg b-cell non-hodgkin lymphoma activ safeti dose-adjust infusion cyclophosphamid doxorubicin vincristin prednison chemotherapi rituximab elderli patient poor-prognost untreat diffus larg b-cell non-hodgkin lymphoma,0,1.0,0.0,2177
352,theophyllin asthma maximum serum level num micrograms/ml num2num micrograms/ml attain num num hour dose t1 t2 coincid perfectli time critic morn dip num-num anumm nocturn excess num2num t1 num2num t2 circadian-tailor asymmetr dosag regimen prove take account chronopatholog asthma chronopharmacokinet theophyllin sustained-releas prepar,0,1.0,0.0,2801
353,sunitinib manag neuroendocrin tumor believ studi sunitinib octreotid neoadjuv intent prepar tumor resect warrant strategi improv cur manag neuroendocrin tumor,0,1.0,0.0,2702
354,curcumin cancer achiev effect cancer prevent curcumin need find new method enhanc effect curcumin diet,0,1.0,0.0,2113
355,zanamivir ili uncontrol open-label multicentr studi evalu antivir activ safeti inhal zanamivir rotadisk via diskhal devic num2 mg administ twice daili num day subject num2 year old ili,0,1.0,0.0,1943
356,adefovir hbv-infect two de novo hbv-infect patient ymdd mutat given adefovir combin lamivudin liver function gradual improv follow-up period,0,1.0,0.0,1011
357,sunum4 tumor tripl combin use low-tox drug exposur pemetrex sunum4 result greater respons treatment alon combin two modal test endotheli tumor cell model,0,0.8143,0.1857,2232
358,gaba ischemia report downregul gaba receptor gaba r express affect mrna protein level gaba r subunit hippocamp neuron subject oxygen-glucos depriv ogd vitro model ischemia,0,1.0,0.0,1015
359,bp cancer hypercalcemia bp standard treatment cancer hypercalcemia dose num2 mg pamidron num4 mg clodron recommend former compound potent longer last effect,0,1.0,0.0,1907
360,mg. hk conclud signific loss mg occur presenc neg mg balanc mg defici endurance-train subject prolong exposur hk daili mg supplement mg load test,0,0.8207,0.1793,2124
361,desmopressin multipl sclerosi examin safeti efficaci desmopressin three dose given women multipl sclerosi treat nocturia without enuresi,0,1.0,0.0,1546
362,bendamustin indol lymphoma bendamustin b mitoxantron shown potent cytotox drug treatment relaps refractori indol lymphoma,0,1.0,0.0,738
363,num num-dihydroxybenzaldehyd oncogenesi sinc ckii involv cell prolifer oncogenesi result suggest num num-dihydroxybenzaldehyd may function inhibit oncogen diseas least part inhibit ckii activ,0,0.8267,0.1733,2862
364,pristinamycin staphylococcu epidermidi staphylococcu epidermidi num3 isol search strain pristinamycin resist,0,1.0,0.0,83
365,androgen ar/androgen receptor drug design suppress androgen receptor ar signal restor follow first-lin androgen depriv therapi,0,1.0,0.0,701
366,aspart hepat c. includ requir improv enzymolog screen despit introduct test hepat c imbal popular unexplain chronic aminotransferas elev effort solv inher problem inadequ attempt use metabol chang hepatocyt improv diagnosi prognosi pathophysiolog understand viral liver diseas remark investig num'-num'-oligoadenyl synthetas better control interferon therapi chronic viral hepat use enzym marker etiolog particularli detect alcohol induc liver diseas continu prefer aminotransferas scenario although ratio aspart aminotransferas alanin aminotransferas mitochondri aspart aminotransferas total aspart aminotransferas activ larg depend sever intralobular local damag stage liver diseas,0,1.0,0.0,1244
367,doxorubicin tumor th-num3 given num hr doxorubicin docetaxel increas dna damag apoptosi throughout tumor compar chemotherapi alon,0,1.0,0.0,1105
368,triphosph cll major case num2 analogu triphosph present num2 hour infus indic prolong retent triphosph cll cell,0,1.0,0.0,530
369,testosteron surgic menopaus testosteron defici menopaus women common appreci particularli patient hormon replac surgic menopaus,0,1.0,0.0,109
370,vardenafil ed/erectil dysfunct vardenafil report improv success rate mainten erect suffici complet intercours sep-num compar placebo erectil dysfunct ed patient attempt intercours earli num2 minut dose,0,1.0,0.0,655
371,steroid laboratori abnorm patient requir steroid repeat cours cyclophosphamid manag lupu nephriti ursodeoxychol acid ursolit administr result amelior cholestat laboratori abnorm,0,1.0,0.0,2381
372,oxygen hypertens reactiv oxygen speci vascular biolog role arteri hypertens,0,0.8025,0.1975,2715
373,aspirin unusu burn injuri unusu burn injuri due applic white vinegar aspirin mixtur,1,0.0,1.0,9
374,acrylamid toxic present review focus sever advers health effect acrylamid includ mutagen genotox carcinogen neurotox reproduct toxic possibl outcom childhood exposur babi food infant formula,1,0.0,1.0,13
375,methotrex toxic methotrex not remission-induc drug may dose-limit toxic,1,0.0,1.0,14
376,num2 -hete melanoma result demonstr num2 -hete/num2 -hete activ erk fak signal pathway therebi upregul adhes metastat potenti melanoma cell,1,0.3548,0.6452,16
377,methadon death control studi covari patient receiv methadon num2 increas risk death follow-up period adjust hazard ratio hr numnum2 num2 ci numnum2-numnum2 pua uanumnum3 result num2 num2 ci num2-num3 excess death per num2uanum3 person-year follow-up,1,0.0,1.0,21
378,acetaminophen poison acetaminophen wide use human be analges purpos one frequent caus poison cat,1,0.0,1.0,26
379,acetaminophen hepat failur acetaminophen-poison cat develop methemoglobinemia sometim hepat failur,1,0.0,1.0,29
380,morphin delirium although recent studi suggest opioid rotat could effect treatment strategi morphine-induc delirium no prospect studi investig treatment effect opioid rotat use fentanyl,1,0.3995,0.6005,31
381,mitoxantron cardiotox explor potenti dexrazoxan suppress subclin cardiotox ms patient receiv mitoxantron,1,0.3942,0.6058,37
382,cyclosporin headach headach symptom num2 patient receiv cyclosporin and/or tacrolimu organ transplant retrospect assess,1,0.0,1.0,80
383,levodopa dyskinesia levodopa treatment parkinson 's diseas effect mani type advers event complic diseas cours especi dyskinesia,1,0.20230000000000006,0.7977,81
384,num-ht contract ketanserin-resist compon num-ht-induc contract found -log ecnum2 num f1 numnum2 num3 nm ketanserin -log ecnum2 num f1 numnum2 num4 nm ketanserin,1,0.2028,0.7972,82
385,duloxetin insomnia gener duloxetin well toler num2 patient achiev maximum dose insomnia asthenia advers event report statist significantli p .num2 frequent duloxetine-tr patient compar placebo-tr patient,1,0.3882,0.6118,100
386,steroid ulcer disease/ulc although possibl associ steroid therapi peptic ulcer diseas well known need ulcer prophylaxi therapi infant not unanim accept,1,0.1868,0.8132,112
387,carbon monoxid toxic carbon monoxid toxic,1,0.3731,0.6269,117
388,clozapin cardiomyopathi clozapin known caus cardiac side effect includ myocard pericard cardiomyopathi,1,0.0,1.0,124
389,lithium toxic research use standard leach test life-cycl impact assess lcia hazard assess model evalu hazard wast classif resourc deplet potenti toxic potenti lithium batteri use cellphon,1,0.1936,0.8064,136
390,latanoprost pain median visual analog pain-scal score acetazolamid latanoprost travoprost brinzolamid timolol group num0a1numnum2 num0a1numnum2 num0a1numnum2 num0a1numnum2 num0a1numnum2 respect,1,0.3786000000000001,0.6214,151
391,cyclophosphamid hemorrhag cystiti bk virus-associ hemorrhag cystiti pediatr cancer patient receiv high-dos cyclophosphamid,1,0.0,1.0,156
392,aflatoxin cancers/liv cancer liver cancer one common cancer worldwid particularli asia africa infecti hepat aflatoxin exposur common,1,0.20109999999999995,0.7989,180
393,corticosteroid cataract howev oral corticosteroid user higher risk cataract num/num4 person-year,1,0.0,1.0,185
394,manidipin dizzi two case delapril group withdrawn studi intoler cough one case manidipin group intoler dizzi headach,1,0.1807,0.8193,191
395,clozapin glucos intoler accumul data develop glucos intoler adult receiv clozapin closer monitor bodyweight fast blood glucos imper,1,0.3944,0.6056,195
396,lidocain tn recoveri unassist ambul spontan void occur earlier lidocain associ markedli higher incid tn,1,0.2109,0.7891,215
397,nac hepat failur male cat seem suscept femal cat acetaminophen toxicosi num male die hepat failur num cat given acetaminophen/methylen blue num given acetaminophen/nac/methylen blue,1,0.17759999999999998,0.8224,228
398,indomethacin necrot enterocol antenat indomethacin may associ increas risk periventricular leukomalacia necrot enterocol prematur infant therefor use judici tocolysi,1,0.0,1.0,245
399,acetaminophen hepat failur male cat seem suscept femal cat acetaminophen toxicosi num male die hepat failur num cat given acetaminophen/methylen blue num given acetaminophen/nac/methylen blue,1,0.0,1.0,249
400,ethylen glycol acidosi ingest ethylen glycol either accident suicid attempt character sever acidosi calcium oxal crystal format deposit wide varieti end organ effect may fatal,1,0.0,1.0,253
401,ginkgolid hemorrhag concentr gener num3 time higher peak plasma valu measur oral intak egb num3 recommend dose num3 num3 mg. paf 'weak platelet activ not appear import primari hemostasi result rise seriou doubt paf antagonist effect ginkgolid could respons hemorrhag patient take egb num3,1,0.2004,0.7996,257
402,ach/acetylcholin ad/alzheim 's diseas alzheim 's diseas ad associ defici acetylcholin ach forebrain correl brain patholog cognit dysfunct,1,0.3775,0.6225,292
403,paraquat poison paraquat num num'-dimethyl-num num'-bipyridinium chlorid pq non-select herbicid pq poison accident intent ingest caus numer fatal around world everi year,1,0.0,1.0,293
404,simvastatin infect although simvastatin patient improv significantli third day num2num vs. num2num p numnum3 non-signific increas mortal greater proport infect odd ratio num confid interv numnum2-num simvastatin group main safeti concern,1,0.1916,0.8084,306
405,azathioprin ibd four case nhl ibd cohort sir num2num num2 ci num-num2 p=numnum4 receiv immunosuppress therapi azathioprin n=num methotrex n=num methotrex cyclosporin n=num,1,0.3764,0.6236,342
406,loratadin increas ocular discomfort loratadin cetirizin hydrochlorid induc sign symptom associ ocular dryness includ increas corneal conjunctiv stain decreas tfbut increas ocular discomfort healthi individu,1,0.20420000000000005,0.7958,346
407,barbitur respiratori depress refractori gcse often difficult treat tradit therapi barbitur induc hypotens respiratori depress prolong recoveri,1,0.0,1.0,360
408,aspirin ulcer endoscopi frequent reveal gastroduoden disord among low-dos aspirin user administr ba enteric-co aspirin warrant concern gastroduoden ulcer,1,0.0,1.0,369
409,steroid cryptococcosi sudden rapid deterior death rare consequ dissemin cryptococcosi steroid may worsen cours diseas,1,0.19410000000000005,0.8059,382
410,vancomycin corynebacterium falsenii bacteremia corynebacterium falsenii bacteremia occur infant vancomycin therapi,1,0.0,1.0,384
411,hbsag hepatocellular carcinoma cigarett smoke heavi alcohol consumpt hbsag independ associ increas risk mortal hepatocellular carcinoma not interact synergist,1,0.0,1.0,389
412,silicon granulomat pneumon report case chronic progress granulomat pneumon respons subcutan silicon inject transgend male-to-femal patient infect human immunodefici viru num hiv-num,1,0.0,1.0,394
413,acebutolol scle although first report acebutolol-induc scle awar occurr avoid acebutolol recommend patient stigmata lupu erythematosu,1,0.0,1.0,395
414,vinca alkaloid peripher neuropathi microtubul inhibitor mti -base chemotherapi use treatment breast cancer -- includ vinca alkaloid taxan epothilon -- known associ peripher neuropathi,1,0.0,1.0,408
415,methylen blue hepat failur male cat seem suscept femal cat acetaminophen toxicosi num male die hepat failur num cat given acetaminophen/methylen blue num given acetaminophen/nac/methylen blue,1,0.2149,0.7851,411
416,docetaxel toxic given doxorubicin docetaxel th-num3 complement enhanc anticanc effect perivascular hypox region also increas toxic,1,0.0,1.0,418
417,no tension-typ headach sinc calcineurin inhibitor known influenc renal metabol no key molecul tension-typ headach migrain interest whether calcineurin inhibitor might chang no metabol hbmec well,1,0.21200000000000008,0.7879999999999999,419
418,hydrocortison cognit distort howev strong consist posit associ daili hydrocortison dose preval maladapt person trait inum ident problem cognit distort compuls restrict express callous opposition reject conduct problem social avoid narciss insecur attach p numnum2,1,0.37799999999999995,0.622,421
419,aspirin stroke multivari analysi use calcul odd ratio recurr stroke recurr stroke death aspirin treatment failur patient durat avail follow-up num month toast patient num2 month nind rt-pa trial patient,1,0.20109999999999995,0.7989,426
420,roxithromycin ten episod ten probabl drug roxithromycin induc,1,0.0,1.0,427
421,cocain addict studi analyz suggest potenti role nac treatment addict especi cocain cannabi depend,1,0.3925,0.6075,432
422,ramosetron abdomin pain ramosetron potent select serotonin num-ht num receptor antagonist shown affect abnorm colon function abdomin pain anim,1,0.1957,0.8043,440
423,adr/adriamycin cardiac toxic adriamycin adr potent anticanc drug known caus sever cardiac toxic,1,0.0,1.0,442
424,glucos pleural thicken develop pleural thicken relat level pleural fluid glucos p numnum2,1,0.0,1.0,447
425,reboxetin anxieti irrit anxieti sleep disturb dri mouth common side effect reboxetin,1,0.0,1.0,461
426,aza toxic signific proport studi cohort rheumatolog patient aza drug-rel toxic result discontinu aza,1,0.2028,0.7972,478
427,quinotrierixin endoplasm reticulum paradox quinotrierixin exacerb endoplasm reticulum stress-induc phosphoryl eif2 turn led decreas protein translat,1,0.3943,0.6057,480
428,pcp nasal carcinoma although pcp not classifi human carcinogen epidemiolog observ suggest exposur chlorophenol gener pcp solut particular may result increas risk certain malign disord nasal carcinoma soft tissu sarcoma,1,0.0,1.0,509
429,axitinib palmar-plantar erythrodysaesthesia toler profil gener consist vegf receptor inhibitor axitinib associ numer lower incid palmar-plantar erythrodysaesthesia cutan toxic anaemia sorafenib phase iii trial,1,0.3993,0.6007,521
430,cisplatin toxic determin patient prefer improv chemotox treatment advanc bladder cancer convent treatment advanc bladder cancer methotrex vinblastin doxorubicin plu cisplatin mvac median surviv num year signific toxic,1,0.3855,0.6145,523
431,mtx toxic result suggest polymorph abcc4 abcc2 could novel marker mtx toxic pediatr,1,0.3973,0.6027,524
432,cocain hyperthermia lethal effect cocain uniqu among illicit drug cocain propens caus hyperthermia,1,0.2067,0.7933,525
433,carmustin ocular toxic articl discuss ocular toxic six patient advanc nonpretr colorect cancer receiv megados carmustin mitomycin support autolog bone marrow transplant,1,0.3884,0.6116,531
434,ginkgolid bleed complic inhibit platelet activ factor paf -induc aggreg human thrombocyt ginkgolid consider possibl bleed complic oral intak ginkgo biloba extract,1,0.1904,0.8096,542
435,atp avb unusu behaviour could interpret abnorm suscept atp patient could consid 'atp-sensit avb,1,0.3702,0.6298,547
436,sodium nitroprussid toxic cyanid toxic complic sodium nitroprussid administr,1,0.0,1.0,552
437,oleic acid adrp induct adrp tg accumul also observ oleic acid-tr huh-num human liver cell,1,0.3688,0.6312,556
438,vinflunin neurotox articl provid overview incid characterist manag mti-associ neurotox known vinca alkaloid taxan well newer agent vinflunin ixabepilon,1,0.3726,0.6274,561
439,num2 -hete melanoma endogen releas num2 -hete/num2 -hete host organ may affect metastat potenti melanoma,1,0.3921,0.6079,563
440,num-ht contract ketanserin-resist compon num-ht-induc contract found -log ecnum2 num f1 numnum2 num3 nm ketanserin -log ecnum2 num f1 numnum2 num4 nm ketanserin,1,0.2056,0.7944,569
441,ethanol muscl atrophi present num alcohol myopathi past present futur timothi j. peter victor r. preedi num protein adduct type ii fiber-predomin muscl ethanol-f rat simon worral seppo parkkila onni niemela num hydroperoxid chang alcohol myopathi junko adachi migiwa asamo yasuhino ueno num close associ testicular atrophi muscl atrophi increas protein catabol chronic ethanol administr kunihiko takeda masayoshi yamauchi kazuhiko sakamoto masaru takagi hisato nakajima gotaro toda,1,0.0,1.0,573
442,melatonin hcc/apoptosi hepatocellular carcinoma melatonin induc apoptosi hepatocellular carcinoma hcc experiment studi effect melatonin endoplasm reticulum er stress-induc apoptosi hcc not test,1,0.1964,0.8036,579
443,duloxetin asthenia gener duloxetin well toler num2 patient achiev maximum dose insomnia asthenia advers event report statist significantli p .num2 frequent duloxetine-tr patient compar placebo-tr patient,1,0.0,1.0,598
444,calcium death cardiomyocyt calcium ca num+ load recogn major factor acut ischaemia-reperfus patholog promot cell death contractil dysfunct arrhythmogen activ,1,0.21419999999999995,0.7858,620
445,olanzapin bodyweight gain quetiapin appear increas risk sedat bodyweight gain albeit less olanzapin,1,0.39299999999999996,0.607,643
446,asa ulcer usual low dose asa relat ulcer reason small asymptomat probabl heal period week month,1,0.0,1.0,644
447,strychnin convuls compound also report activ against convuls induc bicucullin picrotoxin strychnin,1,0.1966,0.8034,649
448,tamoxifen uterin cancer object studi determin percentag women develop uterin cancer num2 month discontinu tamoxifen past user compar clinic patholog featur women develop uterin cancer tamoxifen therapi within num2 month stop therapi recent user,1,0.389,0.611,651
449,venlafaxin hypertens num2num patient develop hypertens start treatment venlafaxin,1,0.0,1.0,659
450,epothilon peripher neuropathi microtubul inhibitor mti -base chemotherapi use treatment breast cancer -- includ vinca alkaloid taxan epothilon -- known associ peripher neuropathi,1,0.3914,0.6086,663
451,atp/adenosin triphosph atrioventricular block/avb sought investig patient syncop relationship document paroxysm atrioventricular block avb unknown mechan avb induc adenosin triphosph atp inject,1,0.1907,0.8093,681
452,epothilon neuropathi epothilon new class mti may associ grade num/num peripher neuropathi howev neuropathi associ ixabepilon novel epothilon b analog gener mild moder revers baselin grade num level,1,0.2024,0.7976,689
453,nmda pain mice enhanc function forebrain nmda receptor demonstr select enhanc persist pain allodynia,1,0.3995,0.6005,692
454,lindan farmer 's lung insecticid ddt lindan aldicarb posit associ farmer 's lung among farmer,1,0.0,1.0,708
455,paracetamol hypotens analysi cycl suggest hypotens paracetamol caus reduct cardiac index system vascular resist,1,0.0,1.0,727
456,hydroxyzin cn dysfunct children diphenhydramin hydroxyzin effect h1-receptor antagonist medic caus cn dysfunct evidenc increas pnum3 latenc measur cognit function increas subject somnol,1,0.0,1.0,739
457,nicotin vestibular dysfunct data support view measur advers effect reflect dose-depend nicotine-induc vestibular dysfunct,1,0.3972,0.6028,742
458,oxaliplatin peripher sensori neuropathi acut revers cumul peripher sensori neuropathi observ frequent oxaliplatin treatment limit use,1,0.2017,0.7983,747
459,tamoxifen breast cancer/uterin cancer greater num-fold increas risk uterin cancer women breast cancer expos tamoxifen,1,0.0,1.0,752
460,aspirin epigastr pain aspirin group complic gastrointest symptom mainli epigastr pain no frank bleed observ,1,0.0,1.0,753
461,quinin hear loss revers hear loss known complic follow administr quinin salicyl nonsteroid anti-inflammatori drug erythromycin,1,0.0,1.0,757
462,asenapin extrapyramid symptoms/ep pool analysi monotherapi trial common advers event occur num patient twice incid placebo report acut phase asenapin monotherapi bipolar mania somnol dizzi extrapyramid symptom ep akathisia increas bodyweight similar natur occur longer-term monotherapi asenapin,1,0.0,1.0,759
463,chloroxylenol dermat chloroxylenol caus hand dermat plumber,1,0.0,1.0,765
464,picrotoxin convuls compound also report activ against convuls induc bicucullin picrotoxin strychnin,1,0.0,1.0,767
465,methotrex toxic determin patient prefer improv chemotox treatment advanc bladder cancer convent treatment advanc bladder cancer methotrex vinblastin doxorubicin plu cisplatin mvac median surviv num year signific toxic,1,0.1826,0.8174,768
466,dmba mammari carcinoma vorozol like ovariectomi almost complet reduc tumor growth dmba-induc mammari carcinoma model rat,1,0.19820000000000004,0.8018,771
467,num-ht contract ring endotheli function attenu enzymat treatment num-ht caus contract -log ecnum2 num partial block ketanserin,1,0.0,1.0,786
468,cisplatin toxic result demonstr cisplatin-caus hemosiderin deposit spleen provid valuabl clue understand molecular basi toxic cisplatin hemosiderin accumul iron metabol vivo,1,0.3786000000000001,0.6214,793
469,ecstasi infect depress memori problem anxieti mood fluctuat poor concentr infect tremors/twitch weight loss significantli associ extent ecstasi use,1,0.0,1.0,804
470,steroid cataract retrospect observ cohort studi cataract incid conduct among user oral intranas steroid identifi unit kingdom-bas gener practic research databas nest case-control analysi control confound factor,1,0.3886,0.6114,808
471,budesonid allergi studi show allerg skin reaction may occur patient contact allergi budesonid inhal form drug use,1,0.0,1.0,817
472,zotepin myoclon seizur report occurr myoclon seizur progress gener tonic-clon seizur zotepin along clear tempor associ dose depend modul evid case,1,0.19299999999999995,0.807,820
473,probenecid pancytopenia patient rheumatoid arthriti develop life-threaten pancytopenia result low dose oral methotrex mtx toxic potenti probenecid,1,0.20809999999999995,0.7919,824
474,aspirin toxic low dose aspirin asa use associ wide rang advers side effect upper gastrointestin gi tract rang troublesom symptom without mucos lesion seriou toxic includ ulcer gi bleed perfor even death,1,0.0,1.0,826
475,sumatriptan contract ring intact endothelium num-ht1-like-select agonist sumatriptan caus small contract -log ecnum2 num intrins activ numnum2 respect num-ht resist blockad num4 nm ketanserin antagon num3 nm methiothepin,1,0.0,1.0,844
476,noradrenalin thermal hyperalgesia howev iontophoresi noradrenalin thermal hyperalgesia greater guanethidine-pretr site salin pretreat site,1,0.3819,0.6181,858
477,quetiapin bodyweight gain quetiapin appear increas risk sedat bodyweight gain albeit less olanzapin,1,0.0,1.0,859
478,vancomycin recurr diseas vancomycin metronidazol use treat clostridium difficile-associ diseas cdad past num2 year approxim num2 patient develop recurr diseas,1,0.0,1.0,861
479,vancomycin toxic data suggest dose-depend toxic cefuroxim vancomycin hcec vitro narrow rang safeti,1,0.3955,0.6045,871
480,cyclophosphamid toxic despit continu therapeut success cyclophosphamid long-term follow-up patient wegen granulomatosi led increas concern toxic result prolong cyclophosphamid therapi encourag investig therapeut regimen,1,0.0,1.0,875
481,oestrogen breast cancer addit oestrogen play import role breast cancer develop oestron sulphat e1 might main sourc activ oestrogen breast,1,0.3921,0.6079,892
482,leuprolid weight gain num2 patient receiv leuprolid num weight gain num kg,1,0.0,1.0,894
483,dexamethason vte set imids-bas treatment associ rate vte reach valu num2 num2 particularli dexamethason chemotherapi ad,1,0.3943,0.6057,904
484,chromium vi toxic base experiment studi substanti amount ascorb acid would need administ prefer parenter soon exposur prevent system toxic chromium vi human,1,0.0,1.0,919
485,num2 -hete scid adhes lung metastasi human melanoma cell cnum2 nod/scid mice also potenti co-treat num2 -hete,1,0.3926,0.6074,923
486,olanzapin glucos dysregul new onset diabet mellitu spite conflict report emerg evid least two atyp antipsychot clozapin olanzapin associ increas risk develop glucos dysregul new onset diabet mellitu,1,0.0,1.0,927
487,clozapin myocard clozapin known caus cardiac side effect includ myocard pericard cardiomyopathi,1,0.0,1.0,936
488,oxygen toxic exposur high oxygen concentr produc toxic free radic releas,1,0.0,1.0,937
489,clozapin pericard prompt case clozapine-rel pericard adolesc undertook retrospect chart review discov whether unrecogn case myocard pericard cardiomyopathi among children adolesc young adult treat clozapin,1,0.0,1.0,943
490,medroxyprogesteron acetate/mpa cholelithiasi five out forty-f adult men num2 year age less receiv least six month medroxyprogesteron acet mpa depo provera im num3-num3 mg/week prevent sex-offend genital-mutil behavior develop symptomat cholelithiasi,1,0.1958,0.8042,953
491,mitomycin ocular toxic ocular toxic system chemotherapi megados carmustin mitomycin,1,0.3861,0.6139,958
492,no endotheli dysfunct pathophysiolog mechan headach may connect endotheli dysfunct term increas product no,1,0.3963,0.6037,967
493,sodium abdomin pain taxin taxin b toxic alkaloid taxu block cardiac sodium calcium channel caus nausea vomit abdomin pain cardiac arrhythmia respiratori distress coma seizur death yew poison,1,0.0,1.0,975
494,fluoroquinolon tendinopathi fluoroquinolon antibiot therapi recogn poorli understood caus achil tendinopathi,1,0.3931,0.6069,991
495,heparin osteoporosi fondaparinux not inhibit osteoblast prolifer vitro may reduc risk heparin-induc osteoporosi associ long-term heparin administr,1,0.0,1.0,1001
496,chromium vi toxic system toxic may occur follow ingest chromium vi salt chromium vi -induc skin burn inhal chromium vi occur occup,1,0.0,1.0,1010
497,paroxetin sexual dysfunct ssri-induc sexual dysfunct describ fluoxetin paroxetin sertralin fluvoxamin num-num2 week therapi,1,0.20940000000000009,0.7906,1021
498,anthracyclin cardiotox acut promyelocyt leukaemia apl treatment often includ high cumul dose anthracyclin caus long-term cardiotox,1,0.0,1.0,1030
499,estrogen stroke epht recruit num4-num4 women 's health initi whi usa decid stop estrogen-progestin trial mean num year juli num4 increas risk breast cancer later num4 estrogen-onli trial ht increas risk stroke decreas risk hip fractur not affect coronari heart diseas incid,1,0.0,1.0,1037
500,posaconazol gastric intrahepat mucormycosi knowledg first report case extens gastric intrahepat mucormycosi respond combin posaconazol lamb without surgic debrid,1,0.391,0.609,1066
501,ascorb acid acut oxal nephropathi howev ascorb acid metabol precursor oxal administr ascorb acid high dose could lead acut oxal nephropathi particularli presenc renal failur,1,0.0,1.0,1071
502,ursodeoxychol acid/ursolit laboratori abnorm patient requir steroid repeat cours cyclophosphamid manag lupu nephriti ursodeoxychol acid ursolit administr result amelior cholestat laboratori abnorm,1,0.38799999999999996,0.612,1098
503,guanethidin thermal hyperalgesia observ indic prolong deplet adrenerg store guanethidin induc adrenerg supersensit cutan vessel adrenerg supersensit enhanc thermal hyperalgesia presenc noradrenalin,1,0.0,1.0,1116
504,furosemid thrombocytopenia num-year case furosemide-induc immun thrombocytopenia,1,0.3878,0.6122,1124
505,androgen prostat cancer androgen affect growth prostat gland mani prostat cancer,1,0.1846,0.8154,1125
506,num-aza-num'-deoxycytidin necrosi find clinic achiev level num-aza-num'-deoxycytidin num-aza-dc potent inhibitor dna methyl modifi chromatin restor abil tumor necrosi factor alpha tnfalpha induc monocyt differenti acut myeloid leukemia cell nb4 unum3,1,0.3979,0.6021,1126
507,pcp sarcoma although pcp not classifi human carcinogen epidemiolog observ suggest exposur chlorophenol gener pcp solut particular may result increas risk certain malign disord nasal carcinoma soft tissu sarcoma,1,0.0,1.0,1128
508,aspirin respiratori diseas baselin feva lower lung function treatment clinic factor indic poor prognosi aspirin-exacerb respiratori diseas,1,0.2117,0.7883,1134
509,bombesin tumor bombesin significantli stimul growth pt tumor day num2 mice sacrif day num2,1,0.0,1.0,1143
510,methadon death increas risk death observ patient receiv methadon retrospect cohort studi even low dose support recommend not drug first choic noncanc pain,1,0.0,1.0,1144
511,cisplatin hemolyt urem syndrom hemolyt urem syndrom may associ varieti etiolog chemotherapeut agent also report associ hemolyt urem syndrom includ mitomycin cisplatin bleomycin recent gemcitabin,1,0.17520000000000002,0.8248,1145
512,heparin osteoporosi prolong administr heparin prevent treatment venou thromboembol associ risk heparin-induc osteoporosi,1,0.1919,0.8081,1160
513,methotrex acceler nodulosi acceler nodulosi low dose methotrex therapi rheumatoid arthriti,1,0.1733,0.8267,1161
514,num-anilinoacridin cytotox caspase-depend cell death mediat potent cytotox sulfid deriv num-anilinoacridin,1,0.3919,0.6081,1168
515,ssri sexual dysfunct describ occurr manag sexual dysfunct induc select serotonin-reuptak inhibitor ssri provid overview sexual dysfunct report ssri-induc sexual dysfunct manag strategi,1,0.2006,0.7994,1169
516,aspirin gastroduoden disord investig endoscop examin frequenc gastroduoden disord associ buffer enteric-co aspirin eca,1,0.18220000000000008,0.8178,1174
517,gliclazid diabet vascular diseas hemobiolog vascular diseas review potenti gliclazid influenc pathogenesi diabet vascular diseas,1,0.3841,0.6159,1186
518,acebutolol lupu syndrom literatur data along case suggest link acebutolol therapi onset lupu syndrom,1,0.0,1.0,1195
519,fentanyl physic impair cognit physic impair confus abnorm co-ordin occur transderm fentanyl,1,0.0,1.0,1196
520,ecstasi anxieti depress memori problem anxieti mood fluctuat poor concentr infect tremors/twitch weight loss significantli associ extent ecstasi use,1,0.0,1.0,1202
521,aspirin red small eros lesion red small eros aspirin combin group tend exist proxim part small bowel,1,0.3944,0.6056,1204
522,loratadin ocular dryness loratadin cetirizin hydrochlorid induc sign symptom associ ocular dryness includ increas corneal conjunctiv stain decreas tfbut increas ocular discomfort healthi individu,1,0.0,1.0,1216
523,num-fluorouracil excess lacrim ocular side effect system num-fluorouracil therapi includ excess lacrim often resolv cessat therapi,1,0.0,1.0,1219
524,alcohol brain damag drink pattern includ period alcohol consumpt follow abstin bing drink may enhanc possibl brain damag,1,0.0,1.0,1224
525,aspirin bronchial hypersensit g allel ccr3 -num3t g associ persist bronchial hypersensit aspirin,1,0.1863,0.8137,1233
526,cyclophosphamid hc patient hc cyclophosphamid ifosfamid neg bacteri cultur studi bkv,1,0.3994,0.6006,1258
527,cadmium tumorigenesi find demonstr first time cell transform tumorigenesi induc cadmium due least part overexpress tef-num delta novel cadmium-respons proto-oncogen,1,0.2131,0.7869,1261
528,remifentanil hypotens episod hypotens transient reduct splanchnic perfus common patient treat remifentanil compar receiv fentanyl opioid regimen,1,0.0,1.0,1271
529,copper cytotox real-tim monitor copper ions-induc cytotox ei cell chip,1,0.19900000000000007,0.8009999999999999,1288
530,pregabalin dizzi pregabalin well toler common advers event dizzi somnol,1,0.19710000000000005,0.8029,1303
531,atra/all-tran retino acid hl present studi demonstr bufalin enhanc all-tran retino acid atra induc differenti hl-num2 cell accompani up-regul cbl famili ubiquitin ligas,1,0.19900000000000007,0.8009999999999999,1309
532,alcohol cardiomyopathi moreov alcohol abus produc cardiac arrhythmia hypertens cardiomyopathi stroke even sudden death,1,0.0,1.0,1317
533,vemurafenib cancer new agent possess uniqu toxic profil includ immune-rel advers event ipilimumab secondari cutan cancer report vemurafenib use,1,0.0,1.0,1319
534,aldicarb farmer 's lung insecticid ddt lindan aldicarb posit associ farmer 's lung among farmer,1,0.0,1.0,1320
535,roxithromycin advers drug reaction/ten/tox epiderm necrolysi case report highlight rare advers drug reaction oral roxithromycin caus toxic epiderm necrolysi ten,1,0.20540000000000005,0.7946,1326
536,cyanoacryl arrest acut gv bleed cyanoacryl glue inject could achiev arrest acut gv bleed often alcohol num2 vs num2 need rescu surgeri less differ howev not signific,1,0.1828,0.8172,1333
537,mtx toxic slco1b1 transport involv mtx elimin polymorph gene pathway could also role mtx toxic,1,0.19610000000000005,0.8039,1353
538,fentanyl hypoventil contraind manag acut postop pain pain may decreas rapidli circumst fentanyl blood level adjust lead develop life-threaten hypoventil,1,0.1939,0.8061,1363
539,clozapin attrit clozapin uniqu effect refractori schizophrenia treatment attrit high,1,0.3919,0.6081,1381
540,ecstasi depress depress memori problem anxieti mood fluctuat poor concentr infect tremors/twitch weight loss significantli associ extent ecstasi use,1,0.0,1.0,1382
541,quinin ocular toxic quinin ocular toxic treatment blind use therapi vasospasm,1,0.3738,0.6262,1390
542,methamphetamin addict studi evalu role nac cocain depend three studi cannabi depend two studi nicotin depend two studi methamphetamin addict one studi patholog gambl one studi,1,0.2104000000000001,0.7896,1391
543,manidipin headach two case delapril group withdrawn studi intoler cough one case manidipin group intoler dizzi headach,1,0.21519999999999995,0.7848,1397
544,silic lung diseas hypothesi lung diseas silic inhal caus oxid gener,1,0.385,0.615,1405
545,progesteron gallbladd diseas find consist increas incid gallbladd diseas relat high-progesteron state suggest mpa may caus agent cholelithiasi,1,0.20130000000000006,0.7987,1407
546,atp avb patient atp induc long ventricular paus relat avb mean durat num2num rang num num2,1,0.3986,0.6014,1408
547,cd fetal death anim experi high-dos exposur cd induc sever testicular interstiti hemorrhag edema increas incid fetal death placent necrosi,1,0.3955,0.6045,1410
548,salicyl hear loss revers hear loss known complic follow administr quinin salicyl nonsteroid anti-inflammatori drug erythromycin,1,0.0,1.0,1431
549,corticosteroid colon diverticula report describ cours three patient develop perfor colon diverticula tempor relat corticosteroid use,1,0.0,1.0,1437
550,furosemid decreas blood viscos furosemid administr mean arteri blood pressur decreas blood viscos carotid systol shear stress increas group,1,0.3959,0.6041,1438
551,thienopyridin small bowel injuri combin low-dos aspirin thienopyridin exacerb small bowel injuri,1,0.0,1.0,1446
552,perindopril effect stroke reduct lower within-individu visit-to-visit variabl blood pressur read amlodipine/perindopril combin treatment arm ascot studi shown account effect stroke reduct rate combin compar atenolol diuretic-bas therapi despit overal similar blood pressur lower,1,0.17679999999999996,0.8232,1447
553,nicotin dizzi nicotin wellknown unpleas side effect e.g. transient dizzi nausea nicotine-induc nystagmu nin,1,0.0,1.0,1484
554,acebutolol cutan lupu erythematosu acebutolol-induc subacut cutan lupu erythematosu,1,0.1875,0.8125,1490
555,h2o2 patholog lesion patholog lesion deposit igg c3 mpo found immun rat perfus mpo h2o2 without neutral proteas mpo alon rat strain day num day num2,1,0.3861,0.6139,1493
556,fentanyl hypoventil transderm fentanyl administ cautious patient pre-exist condit emphysema may predispos develop hypoventil,1,0.39799999999999996,0.602,1502
557,fatti acid colorect cancer risk colorect cancer may influenc dietari intak variou vitamin miner essenti fatti acid,1,0.1955,0.8045,1507
558,reboxetin dri mouth irrit anxieti sleep disturb dri mouth common side effect reboxetin,1,0.0,1.0,1511
559,acetylcholin spasm major complic spasm provoc test intracoronari inject acetylcholin,1,0.1905,0.8095,1515
560,acetazolamid pain median visual analog pain-scal score acetazolamid latanoprost travoprost brinzolamid timolol group num0a1numnum2 num0a1numnum2 num0a1numnum2 num0a1numnum2 num0a1numnum2 respect,1,0.3955,0.6045,1526
561,bombesin cancer variou studi suggest bombesin gastrin-releas peptid act autocrin growth factor may play role initi progress cancer includ breast,1,0.0,1.0,1530
562,paclitaxel cytotox paclitaxel preferenti cytotox radioresist tumor clone level paclitaxel-induc cytotox significantli p numnum4 influenc raf-num kinas activ level,1,0.0,1.0,1539
563,sorbitol turp syndrom report case hyperglycaemia lactic acidosi complic turp syndrom caus massiv absorpt approxim num2 litr sorbitol- mannitol irrig solut,1,0.0,1.0,1547
564,polychlorin biphenyls/pcb nafld/non-alcohol fatti liver diseas polychlorin biphenyl pcb persist environment toxic present num3 ofaeunum adult dose-depend associ obes non-alcohol fatti liver diseas nafld,1,0.0,1.0,1550
565,clozapin sialorrhea current treatment strategi clozapine-induc sialorrhea,1,0.3843,0.6157,1565
566,tfa coronari heart diseas although increas report effect diet contain tfa risk factor metabol syndrom diabet mellitu coronari heart diseas observ recent year influenc intestin inflamm remain unknown,1,0.0,1.0,1575
567,acetylcholin spasm spasm provoc test use acetylcholin perform care although consid safe reliabl method,1,0.0,1.0,1579
568,mibg pulmonari hypertens num3 i-mibg also use potenti marker pulmonari endotheli cell function may relat pulmonari hypertens,1,0.0,1.0,1584
569,nicotin nausea degre nicotine-induc nausea significantli correl postur imbal,1,0.0,1.0,1587
570,ethanol hyperthermia except one hyperthermia victim influenc ethanol,1,0.21640000000000004,0.7836,1597
571,salmeterol asthma small statist signific increas respiratory-rel asthma-rel death combin asthma-rel death life-threaten experi total popul receiv salmeterol,1,0.0,1.0,1612
572,cd hemorrhag anim experi high-dos exposur cd induc sever testicular interstiti hemorrhag edema increas incid fetal death placent necrosi,1,0.0,1.0,1613
573,clozapin sialorrhea sialorrhea common disabl advers effect clozapin use,1,0.19330000000000008,0.8067,1614
574,thienopyridin small bowel injuri combin low-dos aspirin therapi thienopyridin may exacerb small bowel injuri prevent strategi establish,1,0.0,1.0,1627
575,nickel toxic environment impact associ resourc deplet human toxic mainli associ cobalt copper nickel thallium silver wherea ecotox potenti primarili associ cobalt copper nickel thallium silver,1,0.1955,0.8045,1652
576,iron lung diseas inhal silic dust may caus lung diseas surfac coordin iron subsequ oxid gener via fenton reaction,1,0.2097,0.7903,1656
577,thalidomid vte sinc introduct immunomodulatori deriv imid thalidomid lenalidomid therapeut armamentarium mm vte emerg one lead complic particular patient newli diagnos mm,1,0.0,1.0,1665
578,fatti acid death clear studi other multipl pathway fatti acid palmit lead beta-cel dysfunct death,1,0.3784,0.6216,1678
579,serotonin/num-ht/num-hydroxytryptamin drug depend present review provid overview serotonin num-hydroxytryptamin num-ht 2c receptor relationship drug depend,1,0.3982,0.6018,1683
580,roxithromycin advers drug reaction/ten naranjo advers drug reaction probabl scale suggest likelihood oral administr roxithromycin respons ten 'probabl,1,0.0,1.0,1695
581,aspirin respiratori diseas clinic cours patient aspirin-exacerb respiratori diseas predict prognosi,1,0.0,1.0,1704
582,amphotericin b. nausea analyz daili basi mean chill score meperidin dosag puls rise also higher addit nausea vomit num num2 patient receiv rapid infus versu num num patient receiv slow infus p less numnum2 appear common receiv amphotericin b rapidli,1,0.0,1.0,1705
583,iron tuberculosi increas incid tuberculosi observ among silic worker could explain accumul iron complex dust particl lung made avail dormant mycobacteria virul factor,1,0.0,1.0,1718
584,methylphenid juvenil huntington diseas juvenil huntington diseas exacerb methylphenid case report,1,0.2098,0.7902,1719
585,dihydrotestosterone/dht prostat cancer although androgen effect prostat cell believ dihydrotestosteron dht activ metabolit primarili util prostat cancer cell growth divis,1,0.0,1.0,1724
586,cbnum4 breast cancer result indic cbnum4 potenti respons breast cancer cell tnfalpha suggest ceramid and/or cpla num might involv downstream effector vitamin d-mediat caspase-independ cell death,1,0.3691,0.6309,1738
587,sodium hypertens epidemiolog clinic studi suggest magnesium may reduc frequenc sudden death sodium contribut occurr hypertens calcium may help prevent osteoporosi,1,0.0,1.0,1739
588,fentanyl confus cognit physic impair confus abnorm co-ordin occur transderm fentanyl,1,0.0,1.0,1744
589,corticosteroid/corticosteroid cataract oral corticosteroid user increas risk cataract risk among intranas corticosteroid user unknown,1,0.0,1.0,1746
590,calcium chlorid clonic-ton convuls effect calcium chlorid inject cerebr ventricl group-hous unanaesthet cat upon vocal rage hiss snarl fight attack paw claw defens paw claw bite mydriasi tremor clonic-ton convuls produc carbachol eserin inject similarli investig,1,0.0,1.0,1747
591,ndma cytotox cytotox due exposur ndma partial inhibit antioxid n-acetylcystein ascorb acid butyl hydroxyanisol n-t-butyl-alpha-phenylnitron not potenti upon glutathion deplet,1,0.17820000000000005,0.8218,1753
592,clozapin pericard chart review potenti featur myocard pericard cardiomyopathi children adolesc treat clozapin,1,0.17520000000000002,0.8248,1756
593,anthracyclin cardiotox anthracyclin cardiotox close correl cumul dose great variabl individu suscept dramat increas advanc age,1,0.3908,0.6092,1767
594,morphin opioid rotat twenty-on consecut cancer patient morphine-induc delirium underw opioid rotat fentanyl,1,0.2166,0.7834,1780
595,nickel cancer/nas cancer aim determin whether occup exposur receiv manufactur nickel alloy lead increas risk cancer particular nasal cancer lung cancer,1,0.0,1.0,1784
596,ecstasi memori problem depress memori problem anxieti mood fluctuat poor concentr infect tremors/twitch weight loss significantli associ extent ecstasi use,1,0.0,1.0,1792
597,sorbitol turp syndrom anoth featur turp syndrom hyperglycaemia lactic acidosi caus massiv absorpt sorbitol,1,0.1994,0.8006,1793
598,silicon pneumon silicon commonli use cosmet procedur owe presum inert yield seriou sequela includ acut embol pneumon,1,0.0,1.0,1804
599,ca4p oculomotor nerv palsi dose-limit toxic effect dlt revers ataxia oculomotor nerv palsi occur two patient prostat cancer receiv weekli ca4p num2 mg/m2,1,0.0,1.0,1817
600,arsen trioxid death dynam effect autophagi arsen trioxide-induc death human leukemia cell line hlnum2 cell,1,0.0,1.0,1821
601,num-fluorouracil stenosi sever stenosi puncta canaliculi may associ prolong system num-fluorouracil therapi,1,0.0,1.0,1825
602,ixabepilon peripher neuropathi epothilon new class mti may associ grade num/num peripher neuropathi howev neuropathi associ ixabepilon novel epothilon b analog gener mild moder revers baselin grade num level,1,0.18010000000000004,0.8199,1833
603,vigabatrin vfc summari half children treat vigabatrin demonstr vfc abnorm ocular electrophysiolog studi,1,0.17859999999999998,0.8214,1840
604,gemcitabin hemolyt urem syndrom num2-year-old caucasian male treat four cycl gemcitabin num num3 mg/m2 develop clinic laboratori find compat hemolyt urem syndrom,1,0.20330000000000004,0.7967,1849
605,probenecid toxic patient rheumatoid arthriti develop life-threaten pancytopenia result low dose oral methotrex mtx toxic potenti probenecid,1,0.0,1.0,1855
606,alcohol hepatocellular carcinoma heavi alcohol drink associ hepatocellular carcinoma mortal risk subgroup men test hbsag rr =num num2 ci num num,1,0.1927,0.8073,1880
607,leflunomid rheumatoid nodul antirheumat drug methotrex leflunomid lef infliximab etanercept known risk factor develop rheumatoid nodul,1,0.0,1.0,1881
608,asa gi complic death worst outcom gi complic low dose asa user data aspect scarc,1,0.392,0.608,1882
609,cocain depend studi evalu role nac cocain depend three studi cannabi depend two studi nicotin depend two studi methamphetamin addict one studi patholog gambl one studi,1,0.21900000000000008,0.7809999999999999,1897
610,aspirin cardiovascular complic aspirin group slightli increas rate cardiovascular complic num2num vs num pae=aenumnum3 like reflect increas cardiovascular comorbid led physician recommend aspirin therapi,1,0.1975,0.8025,1898
611,tfa inflamm review describ pro-inflammatori effect tfa diari diet variou system disord also discuss possibl role tfa gut inflamm,1,0.1957,0.8043,1919
612,aminoglycosid toxic haemofiltr indic particularli aminoglycosid toxic,1,0.3692,0.6308,1920
613,nicotin motion sick addit motion stimul aggrav dizzi nausea i.e. nicotin increas sensit motion sick,1,0.0,1.0,1925
614,haloperidol neurolept syndrom patient suffer rare enzym defici develop malign neurolept syndrom treat one singl dose haloperidol,1,0.0,1.0,1935
615,zaleplon reduct sleep latenc result phase ii/iii studi suggest zaleplon num num2 mg produc dose-depend reduct sleep latenc patient suffer primari insomnia,1,0.0,1.0,1936
616,quinin toxic although quinin load dose may effect uniform dose rapid fever clearanc also appear associ higher toxic,1,0.0,1.0,1940
617,yohimbin anxieti yohimbin result signific increas anxieti patient ptsd not healthi subject,1,0.0,1.0,1945
618,aspirin small bowel injuri combin low-dos aspirin thienopyridin exacerb small bowel injuri,1,0.1926,0.8074,1948
619,oleic acid adrp jnum3 murin macrophag incub either vldl oleic acid content adrp triacylglycerol tg increas num- num-fold,1,0.2065,0.7935,1963
620,cholesterol atherosclerosi peroxisom proliferator-activ receptor ppar regul transcript gene involv cholesterol homeostasi thu repres import therapeut target term reduc atherosclerosi,1,0.3781,0.6219,1967
621,num2 -hete melanoma adhes lung metastasi human melanoma cell cnum2 nod/scid mice also potenti co-treat num2 -hete,1,0.3867,0.6133,1982
622,nickel hypersensit claim high correl posit histori nickel hypersensit patch-test result test unnecessari histori hypersensit,1,0.2009,0.7991,1998
623,acetaminophen methemoglobinemia acetaminophen-poison cat develop methemoglobinemia sometim hepat failur,1,0.0,1.0,2002
624,levobupivacain death awak sheep exampl almost num2 levobupivacain requir caus death,1,0.3965,0.6035,2006
625,dihydroergotamin primari headach disord determin dose side effect dihydroergotamin affect outcom primari headach disord,1,0.3961,0.6039,2015
626,aspirin small bowel injuri recent studi small bowel injuri enteropathi associ low-dos aspirin increasingli recogn,1,0.0,1.0,2016
627,morphin analgesia doubl blind cross studi design evalu effect ketamin spinal morphin analgesia termin cancer pain patient,1,0.384,0.616,2028
628,ddt farmer 's lung insecticid ddt lindan aldicarb posit associ farmer 's lung among farmer,1,0.0,1.0,2029
629,diphenhydramin toxic dose-depend toxic diphenhydramin overdos,1,0.0,1.0,2035
630,pah cancer polycycl aromat hydrocarbon pah ubiquit environment pollut toxic focu establish cancer risk human,1,0.2088,0.7912,2039
631,clozapin myocard chart review potenti featur myocard pericard cardiomyopathi children adolesc treat clozapin,1,0.19530000000000008,0.8047,2042
632,norepinephrin asystol num2-year-old male experienc postexercis bradycardia asystol higher basal plasma norepinephrin num3 versu num2 +/- num pg/ml epinephrin num2 versu less num2 pg/ml similar vagal tone vagal tone index numnum2 versu numnum2 +/- numnum2 u compar num close match subject underw unev stress test,1,0.3971,0.6029,2051
633,capecitabin toxic neurotox infrequ report toxic capecitabin,1,0.2007,0.7993,2067
634,taxan peripher neuropathi microtubul inhibitor mti -base chemotherapi use treatment breast cancer -- includ vinca alkaloid taxan epothilon -- known associ peripher neuropathi,1,0.1974,0.8026,2068
635,nmda allodynia mice enhanc function forebrain nmda receptor demonstr select enhanc persist pain allodynia,1,0.1989,0.8011,2090
636,fingolimod neurolog condit report case woman multipl sclerosi develop sever neurolog condit follow natalizumab nzb withdraw soon fingolimod fti initi,1,0.0,1.0,2116
637,adr mitochondri damag electron microscopi reveal dose-depend ultrastructur alter mark mitochondri damag nontransgen mice treat adr not transgen litterm,1,0.3876,0.6124,2125
638,silicon dyspnea receiv silicon inject buttock patient develop rapid onset dyspnea pleurit chest pain fever chill,1,0.0,1.0,2131
639,bombesin gastrinoma demonstr first time bombesin trophic hormon gastrinoma,1,0.387,0.613,2132
640,levodopa anxieti dose-respons relationship levodopa mood anxieti fluctuat parkinson 's diseas double-blind placebo-control studi,1,0.3899,0.6101,2136
641,gemcitabin hemolyt urem syndrom hemolyt urem syndrom may associ varieti etiolog chemotherapeut agent also report associ hemolyt urem syndrom includ mitomycin cisplatin bleomycin recent gemcitabin,1,0.1925,0.8075,2141
642,aza toxic averag initi dose aza prescrib num3anum2 mg. num2 develop aza relat toxic,1,0.0,1.0,2144
643,lithium toxic howev rel contribut aluminum lithium human toxic ecotox could not estim due insuffici toxic data model,1,0.3787,0.6213,2145
644,quinin vasospasm case ocular toxic vasospasm secondari quinin poison describ,1,0.1967,0.8033,2147
645,salmeterol death small signific increas respiratory-rel death num2 vs num2 rr numnum2 num2 ci numnum2 numnum2 asthma-rel death num2 vs num rr numnum2 num2 ci numnum2 num2numnum2 combin asthma-rel death life-threaten experi num2 vs num2 rr numnum2 num2 ci numnum2 numnum2 subject receiv salmeterol vs placebo,1,0.3805,0.6195,2162
646,estrogen breast cancer epht recruit num4-num4 women 's health initi whi usa decid stop estrogen-progestin trial mean num year juli num4 increas risk breast cancer later num4 estrogen-onli trial ht increas risk stroke decreas risk hip fractur not affect coronari heart diseas incid,1,0.3819,0.6181,2164
647,salmeterol asthma imbal occur larg african-american subpopul respiratory-rel death life-threaten experi num2 vs num rr numnum2 num2 ci numnum2 num2numnum2 combin asthma-rel death life-threaten experi num2 vs num rr numnum2 num2 ci numnum2 num2numnum2 subject receiv salmeterol vs placebo,1,0.0,1.0,2169
648,indomethacin periventricular leukomalacia antenat indomethacin associ increas risk periventricular leukomalacia odd ratio num num2 confid interv ci num-num,1,0.0,1.0,2174
649,mtx toxic treatment mtx often caus toxic necessit dose reduct treatment cessat,1,0.0,1.0,2180
650,tianeptin cardiac toxic present studi suggest tianeptin tricycl antidepress endow less cardiac toxic classic tricycl antidepress,1,0.3835,0.6165,2194
651,pah toxic oral ingest pah also caus toxic even affect pharmacokinet behavior therapeut agent,1,0.0,1.0,2248
652,axitinib toxic toler profil gener consist vegf receptor inhibitor axitinib associ numer lower incid palmar-plantar erythrodysaesthesia cutan toxic anaemia sorafenib phase iii trial,1,0.1978,0.8022,2249
653,pcb cancer present review address addit scientif data becam avail atsdr num4 num4 evalu magnitud offset weight evid numer epidemiolog studi exposur pcb not causal associ human cancer conclus num year later meaning evid pcb pose carcinogen risk human,1,0.19220000000000004,0.8078,2250
654,olanzapin mania olanzapin like risperidon also associ onset mania adult,1,0.0,1.0,2253
655,vinblastin toxic determin patient prefer improv chemotox treatment advanc bladder cancer convent treatment advanc bladder cancer methotrex vinblastin doxorubicin plu cisplatin mvac median surviv num year signific toxic,1,0.3955,0.6045,2259
656,nucleosid axon injuri nucleosid revers transcriptas inhibitor human immunodefici viru protein caus axon injuri human dorsal root ganglia cultur,1,0.2049,0.7951,2261
657,nicotin nausea dizzi nausea nin unsteadi also depend nicotin dosag p numnum2 .nicotin blood concentr better predictor tempor depend nystagmu nicotin dosag,1,0.2231,0.7769,2277
658,arsen cytotox knum3 egfp-aqp9 transfect accumul significantli higher level intracellular arsen control knum3 egfp incub as2o3 result significantli increas as2o3-induc cytotox,1,0.3926,0.6074,2286
659,no headach pathophysiolog mechan headach may connect endotheli dysfunct term increas product no,1,0.3793,0.6207,2298
660,silicon granulomat pneumon progress granulomat pneumon respons cosmet subcutan silicon inject patient hiv-num infect case report review literatur,1,0.1903,0.8097,2309
661,capsaicin tactil hyperalgesia/allodynia erb-num3 allevi tactil hyperalgesia induc capsaicin revers tactil allodynia caus spinal nerv ligat variou chemic insult,1,0.20409999999999995,0.7959,2316
662,roxithromycin toxic epiderm necrolysi roxithromycin-induc toxic epiderm necrolysi,1,0.0,1.0,2317
663,doxorubicin toxic determin patient prefer improv chemotox treatment advanc bladder cancer convent treatment advanc bladder cancer methotrex vinblastin doxorubicin plu cisplatin mvac median surviv num year signific toxic,1,0.2097,0.7903,2321
664,ixabepilon neurotox articl provid overview incid characterist manag mti-associ neurotox known vinca alkaloid taxan well newer agent vinflunin ixabepilon,1,0.3988,0.6012,2329
665,bradykinin sindbi viru infect bradykinin enhanc sindbi viru infect human brain microvascular endotheli cell,1,0.3906,0.6094,2330
666,carmustin ocular toxic ocular toxic system chemotherapi megados carmustin mitomycin,1,0.3791,0.6209,2331
667,satur fatti acids/sfa atherosclerosi propos dietari satur fatti acid sfa may also serv endogen ligand tlr2 tlr4 therebi promot diseas associ inflamm dyslipidemia includ atherosclerosi insulin resist,1,0.20640000000000008,0.7936,2348
668,acetaminophen toxicosi male cat seem suscept femal cat acetaminophen toxicosi num male die hepat failur num cat given acetaminophen/methylen blue num given acetaminophen/nac/methylen blue,1,0.0,1.0,2349
669,steroid liver failur report two hepat b viru hbv carrier liver failur withdraw corticosteroid steroid administ treatment seriou asthmat attack,1,0.3888,0.6112,2361
670,lorazepam cognit impair relationship plasma baselin pre-drug gaba concentr cognit impair induc acut oral dose lorazepam num num mg investig num2 healthi elderli individu,1,0.0,1.0,2363
671,nicotin dizzi addit motion stimul aggrav dizzi nausea i.e. nicotin increas sensit motion sick,1,0.1974,0.8026,2369
672,selenium fetal death selenium margin associ reduc risk low birth weight rel risk rr numnum2 num2 ci numnum2 numnum2 p numnum2 increas risk fetal death rr numnum2 num2 ci numnum2 numnum2 p numnum2 no effect risk prematur small-for-gest age birth,1,0.0,1.0,2403
673,simvastatin pad median follow-up num8ueyear num2 patient num receiv atorvastatin num3 patient num receiv simvastatin develop pad hr=numnum2 num2 ci numnum2 numnum2 p=numnum3,1,0.0,1.0,2418
674,chromium vi dermat repeat topic exposur chromium vi may caus allerg contact dermat format chrome ulcer,1,0.0,1.0,2425
675,gnrh submucos myoma spontan expuls submucos myoma might occur administr gnrh agonist henc may accept altern symptomat femal without sexual exposur,1,0.3869,0.6131,2428
676,remifentanil reduct splanchnic perfus episod hypotens transient reduct splanchnic perfus common patient treat remifentanil compar receiv fentanyl opioid regimen,1,0.0,1.0,2440
677,cocain hyperthermia howev cocaine-induc hyperthermia occur primarili hot weather hypothes cocain also impair thermoregulatori adjust mediat heat dissip,1,0.0,1.0,2443
678,tfa metabol syndrom although increas report effect diet contain tfa risk factor metabol syndrom diabet mellitu coronari heart diseas observ recent year influenc intestin inflamm remain unknown,1,0.1969,0.8031,2460
679,levodopa osteoporot fractur calcif tissu int num2 num3-num2 num4 levodopa intak associ increas homocysteinemia known link poorer bone qualiti consequ osteoporot fractur,1,0.0,1.0,2484
680,alcohol stroke moreov alcohol abus produc cardiac arrhythmia hypertens cardiomyopathi stroke even sudden death,1,0.0,1.0,2491
681,h2o2 toxic report h2o2-induc cellular toxic act prdx6 hyperoxid,1,0.0,1.0,2499
682,sodium valproat tubulo-interstiti nephriti tubulo-interstiti nephriti caus sodium valproat,1,0.0,1.0,2501
683,copper cytotox result indic complex quinolinon schiff base copper serv significantli enhanc cytotox,1,0.3927000000000001,0.6073,2507
684,cisplatin cytotox sensit anum3 cell cisplatin cytotox induc p-akt inhibit mediat upregul puma wherea induc p-erk1/num inhibit occur bcl-num downregul,1,0.39399999999999996,0.606,2508
685,sevofluran unconsci author record num2-channel electroencephalogram healthi human particip conscious sevoflurane-induc unconsci recoveri n num2 n num suitabl analysi,1,0.3894,0.6106,2514
686,bicucullin convuls compound also report activ against convuls induc bicucullin picrotoxin strychnin,1,0.0,1.0,2519
687,acebutolol scle present herein first case scle induc acebutolol,1,0.18320000000000008,0.8168,2526
688,adriamycin acut cardiac toxic protect role manganes superoxid dismutas against adriamycin-induc acut cardiac toxic transgen mice,1,0.0,1.0,2533
689,barbitur coma includ 'forc hyperventil paco2 num2 mmhg barbitur coma experiment protocol tri buffer indomethacin induc hypothermia,1,0.3799,0.6201,2541
690,methan constip presenc methan lactulos breath test associ constipation-predomin ib,1,0.0,1.0,2563
691,nickel respiratori cancer excess risk respiratori cancer demonstr group nickel-expos worker,1,0.0,1.0,2569
692,midazolam less hypotens refractori gcse continu inumv midazolam infus num-num mg/kg/hr num mg/kg inumv bolu effect advantag tradit therapi induc less hypotens cardiorespiratori depress easili titrat,1,0.2015,0.7985,2576
693,num-fluorouracil ocular toxic import oncologist ophthalmologist awar potenti ocular toxic num-fluorouracil,1,0.0,1.0,2587
694,amiodaron pneumonia vivo probe-bas confoc laser endomicroscopi amiodarone-rel pneumonia,1,0.0,1.0,2609
695,levobupivacain cardiotox revers levobupivacaine-induc cardiotox also assess,1,0.0,1.0,2612
696,risperidon mania risperidone-induc mania report adult therefor increas caution use decid treat children adolesc risperidon particularli predisposit toward mania,1,0.0,1.0,2613
697,vancomycin corynebacterium falsenii bacteremia give first detail descript clinic signific corynebacterium falsenii bacteremia occur infant vancomycin therapi,1,0.0,1.0,2623
698,chromium vi ulcer repeat topic exposur chromium vi may caus allerg contact dermat format chrome ulcer,1,0.0,1.0,2625
699,cyclosporin headach singl case cyclosporine-induc headach report,1,0.20330000000000004,0.7967,2626
700,sevofluran unconsci furthermor revers disrupt anterior-posterior phase relationship alpha bandwidth identifi correl sevoflurane-induc unconsci,1,0.3945,0.6055,2629
701,testosteron ed ed common symptom patient type num diabet also low testosteron level,1,0.3922,0.6078,2633
702,streptozotocin diabet express pancreat islet mhc class insulin ica num3 tyrosin phosphatas low-dos streptozotocin-induc diabet mice,1,0.1946,0.8054,2642
703,cisplatin apoptot cytotox lung cancer cell knockdown rip1 substanti increas cisplatin-induc apoptot cytotox associ robust jnk activ,1,0.1862000000000001,0.8138,2644
704,aspirin asthma aspirin-intoler asthma aia occur asthma exacerb exposur aspirin,1,0.3928,0.6072,2663
705,thapsigargin endoplasm reticulum xbp1 mrna splice express endoplasm reticulum stress respons gene determin cell expos thapsigargin presenc absenc quinotrierixin,1,0.397,0.603,2669
706,anthracyclin cardiotox establish cancer drug anthracyclin also form ro free radic respons cardiotox anthracyclin,1,0.0,1.0,2673
707,corticosteroid allerg contact dermat allerg contact dermat follow ocular use corticosteroid,1,0.0,1.0,2676
708,furosemid thrombocytopenia report describ case furosemid identifi probabl caus drug-induc thrombocytopenia num2-year-old man chronic symptomat idiopath thrombocytopenia seven year discoveri,1,0.1894,0.8106,2682
709,chloroquin cytotox lc3-ii protein increas treatment num-fu chloroquin potenti cytotox num-fu,1,0.1826,0.8174,2693
710,yohimbin anxieti previous report increas symptom anxieti patient posttraumat stress disord ptsd follow administr beta num-antagonist yohimbin stimul brain norepinephrin releas,1,0.0,1.0,2705
711,tocopherol inflamm pattern dietari intak serum carotenoid tocopherol statu associ biomark chronic low-grad system inflamm cardiovascular risk,1,0.1958,0.8042,2719
712,bortezomib encephalopathi bortezomib-induc posterior revers encephalopathi syndrom clinic imag featur,1,0.19510000000000005,0.8049,2721
713,diphenhydramin cn dysfunct children diphenhydramin hydroxyzin effect h1-receptor antagonist medic caus cn dysfunct evidenc increas pnum3 latenc measur cognit function increas subject somnol,1,0.0,1.0,2727
714,ssri sexual dysfunct manag ssri-induc sexual dysfunct,1,0.18500000000000005,0.815,2728
715,aspirin gastroduoden disord endoscopi frequent reveal gastroduoden disord among low-dos aspirin user administr ba enteric-co aspirin warrant concern gastroduoden ulcer,1,0.1999,0.8001,2740
716,cocain hypermetabol tradit view cocain caus hypermetabol state increas heat product,1,0.0,1.0,2750
717,guanethidin thermal hyperalgesia howev iontophoresi noradrenalin thermal hyperalgesia greater guanethidine-pretr site salin pretreat site,1,0.0,1.0,2754
718,ethanol abdomin pain incid rate abdomin pain procedur ethanol group num2num,1,0.1986,0.8014,2761
719,zotepin seizur advers event zotepin induc seizur publish case report,1,0.0,1.0,2763
720,feiba thrombosi thrombosi rare well-recogn potenti complic factor viii inhibitor bypass activ feiba infus,1,0.0,1.0,2764
721,fentanyl vomit compar oral opioid advantag transderm fentanyl includ lower incid impact advers effect constip nausea vomit daytim drowsi higher degre patient satisfact improv qualiti life improv conveni complianc result administr everi num2 hour decreas use rescu medic,1,0.1884,0.8116,2770
722,pcp chronic poison chronic poison occur mainli sawmil worker peopl live log home treat pcp-contain wood protect formul,1,0.0,1.0,2778
723,morphin delirium primari aim studi clarifi efficaci opioid rotat morphin fentanyl symptom palliat morphine-induc delirium,1,0.0,1.0,2780
724,interferon-alpha symptom depress interferon-alpha ifn-alpha treatment frequent complic symptom depress,1,0.3897000000000001,0.6103,2784
725,levodopa homocysteinemia calcif tissu int num2 num3-num2 num4 levodopa intak associ increas homocysteinemia known link poorer bone qualiti consequ osteoporot fractur,1,0.0,1.0,2794
726,vincristin sensory/motor neuropathi although first-gener vinca alkaloid vincristin associ sever mix sensory/motor neuropathi deficit associ newer agent class eg vinflunin gener milder limit distal sensori sign symptom,1,0.0,1.0,2815
727,fluoxetin sexual dysfunct ssri-induc sexual dysfunct describ fluoxetin paroxetin sertralin fluvoxamin num-num2 week therapi,1,0.1894,0.8106,2825
728,lenalidomid vte sinc introduct immunomodulatori deriv imid thalidomid lenalidomid therapeut armamentarium mm vte emerg one lead complic particular patient newli diagnos mm,1,0.206,0.794,2850
729,acrylamid neurotox present review focus sever advers health effect acrylamid includ mutagen genotox carcinogen neurotox reproduct toxic possibl outcom childhood exposur babi food infant formula,1,0.0,1.0,2859
730,gossypol toxic addit low toxic gossypol thioderiv revers nitric oxid donor physiolog media,1,0.1914,0.8086,2877
731,mannitol turp syndrom report case hyperglycaemia lactic acidosi complic turp syndrom caus massiv absorpt approxim num2 litr sorbitol- mannitol irrig solut,1,0.0,1.0,2899
732,adenosin syncop syncop associ document paroxysm atrioventricular block reproduc adenosin num triphosph inject,1,0.3975,0.6025,2924
733,aza toxic determin current local practic aza dose identifi aza-rel toxic compar local practic british societi rheumatolog bsr recommend,1,0.21930000000000005,0.7807,2938
734,chloroform poison drug condemn num4 without attempt made determin incid so-cal delay chloroform poison result drug still use chloroform controversi remain unsettl day,1,0.1928,0.8072,2946
735,iron cytotox catalas suppress cytotox induc iron ion lunum3 cell wherea clvnum3 mel8 cell ineffect,1,0.0,1.0,2950
736,tacrolimu headach headach symptom num2 patient receiv cyclosporin and/or tacrolimu organ transplant retrospect assess,1,0.3921,0.6079,2952
737,probenecid pancytopenia sever pancytopenia patient take low dose methotrex probenecid,1,0.0,1.0,2964
738,alcohol hepatocellular carcinoma cigarett smoke heavi alcohol consumpt hbsag independ associ increas risk mortal hepatocellular carcinoma not interact synergist,1,0.2036,0.7964,2977
739,levobupivacain toxic cardiac cn toxic levobupivacain strength evid advantag bupivacain,1,0.3865,0.6135,2981
740,asenapin dizzi pool analysi monotherapi trial common advers event occur num patient twice incid placebo report acut phase asenapin monotherapi bipolar mania somnol dizzi extrapyramid symptom ep akathisia increas bodyweight similar natur occur longer-term monotherapi asenapin,1,0.203,0.797,2984
741,cocain hyperthermia mechan cocaine-induc hyperthermia human,1,0.3792,0.6208,3005
742,ixabepilon neuropathi epothilon new class mti may associ grade num/num peripher neuropathi howev neuropathi associ ixabepilon novel epothilon b analog gener mild moder revers baselin grade num level,1,0.0,1.0,3030
743,cholesterol coronari arteri disease/cad commonli agre peopl high blood ldl-cholesterol higher risk coronari arteri diseas cad peopl low blood ldl-cholesterol,1,0.0,1.0,3035
744,methadon hydrochlorid ventricular arrhythmia methadon hydrochlorid may increas risk lethal respiratori depress relat accident overdos life-threaten ventricular arrhythmia,1,0.21650000000000005,0.7835,3040
745,memantin bradycardia littl known cardiovascular effect memantin report bradycardia reduc cardiovascular surviv associ use,1,0.3779,0.6221,3083
